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ABSTRACT
Staphylococcus aureus is a major human pathogen known to cause disease in a wide
range of tissues. In order to thrive in such diverse environments, S. aureus uses multiple adaptive
traits such as trace metal/nutrient acquisition, shifts in metabolic activity, and expression of
detoxification systems, all of which allow the bacterium to proliferate and survive in nutritionally
deficient and inhospitable environments.
One essential metabolite used by S. aureus is lipoic acid, a cofactor of enzyme complexes
used in aerobic metabolism, fatty acid biosynthesis, glycine detoxification, and maintenance of
redox homeostasis. Prior studies in the lab used a genetic approach to define the lipoic acid
biosynthesis and salvage pathways of S. aureus. These studies determined that S. aureus
synthesizes lipoic acid from an octanoic acid precursor, or through salvage mechanisms, where
lipoic acid is acquired from the environment by the action of lipoic acid ligases LplA1 and
LplA2. In addition, it was demonstrated that LplA1, but not LplA2, is necessary for the salvage
of lipoic acid in vitro, whereas both ligases are sufficient to promote infection of tissues in vivo.
Because the LplA2 ligase does not have a discernable function in vitro, its exact role in lipoic
acid salvage is unknown.
Based on this information, I hypothesized that LplA1 and LplA2 may stimulate growth
by using alternate lipoylated substrates. To determine if the ligases use alternate sources of lipoic
acid, I evaluated growth phenotypes by supplementing media with derivatives of lipoic acid. I

xi

found that only LplA1, and not LplA2, can use free lipoic acid and peptide bound lipoic acid to
stimulate bacterial growth in vitro. In order to further elucidate the functional differences and
substrate usage of the ligases, I conducted lipoylation assays with purified recombinant ligases in
the presence of lipoic acid, lipoamide, DKLA, and octanoic acid. My results indicated that LplA1
can directly use lipoic acid to lipoylate GcvH, GcvH-L and E2-OGDH, whereas LplA2 can
directly use lipoic acid to lipoylate E2-PDH, E2-OGDH, E2-BCODH, as well as GcvH-L. These
data suggest that both lipoic acid ligases in S. aureus have preferred targets for lipoylation and
that they can act independently from one another.
Together, these studies highlight the importance of the divergent functions of LplA1 and
LplA2 and may explain why S. aureus thrives so well when faced with low levels of free lipoic
acid during host infection.
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CHAPTER ONE
LITERATURE REVIEW
Introduction
Staphylococcus aureus is a Major Human Pathogen.
Staphylococcus aureus is a Gram-positive commensal bacterium commonly found on the
skin, anterior nares, and in the gastrointestinal tract. It is estimated that up to 30% of the world’s
population is asymptomatically colonized with S. aureus (1; 2). However, upon a breach in
physical barriers such as the skin, S. aureus can become a major human pathogen and is known
to cause a wide range of infections, including mild skin and soft tissue infections (SSTI),
bacteremia, sepsis, and osteomyelitis (1; 2; 3). Numerous factors can make a person more
susceptible to S. aureus infections such as the presence of foreign bodies including catheters,
pace makers, and prostheses. In addition, patients who have recently undergone surgery or are
immunocompromised are also at an increased risk of S. aureus infections (4). Due to a rise in
antibiotic resistant strains known as methicillin resistant S. aureus (MRSA), it has become
increasingly difficult to treat S. aureus infections, leading to greater morbidity and mortality (1).
Traditionally, MRSA infections were commonly found in healthcare settings, however in recent
years there has been an increase in community-associated methicillin resistant S. aureus (CAMRSA) infections, leading to the spread of MRSA among healthy individuals (4; 5; 6; 7).
Studies suggest that CA-MRSA strains exhibit increased virulence due, in part, to a greater
production of S. aureus peptides that recruit and lyse human neutrophils (8). However, virulent
1
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S. aureus strains also contain a significant amount of genetic diversity, a trait that likely has
allowed S. aureus to acquire additional virulence mechanisms (8; 9; 10). This constant
acquisition of new traits, allows S. aureus to evade modern therapeutics such as antibiotics,
making it increasingly difficult to treat MRSA infections (8; 9; 10). Due to the increased
prevalence of S. aureus infections in the community, it is imperative for us to deepen our
knowledge of the pathways S. aureus uses to colonize and proliferate in the host. These new
findings may lead to the development of novel therapeutics that can specifically target the
essential pathways that S. aureus requires for survival.
S. aureus Expresses a Multitude of Virulence Factors that Facilitate Colonization and
Survival in the Host Environment.
S. aureus infects a wide array of tissues such as the skin, bones, heart, kidney, and joints
(2). Its ability to colonize and proliferate in such diverse environments is directly linked to the
production of virulence factors that allow the bacterium to adhere to surfaces, evade and
suppress the immune system, release toxins, and take up trace nutrients (11; 12; 13; 14; 15).
In order to initiate colonization, S. aureus uses surface proteins to adhere to plasma or
extracellular matrix (ECM) components (13; 16). The largest class of surface proteins in S.
aureus are called microbial surface component recognizing adhesive matrix molecules
(MSCRAMMs) (17). One class of MSCRAMMs, the fibronectin-binding proteins A and B
(FnbpA and FnbpB), allows S. aureus to bind to osteoblasts resulting in the formation of
biofilms (18). Not only is this class of surface proteins vital for S. aureus to adhere to different
surfaces, they are also important for immune evasion (12). Protein A, which is also part of the
MSCRAMM family, binds to the Fcg domain of immunoglobins resulting in the impairment of
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phagocytic leukocytes and inhibits the activation of the complement cascade (13; 19). The ability
to adhere to a wide range of host tissues is one of the traits that sets S. aureus apart from other
pathogens.
In addition to producing surface adhesion molecules, S. aureus also secretes toxins,
which target the membrane of the host cells resulting in the efflux of metabolites and other
molecules (20). Some well-known S. aureus pore-forming toxins include the a-toxin and
bicomponent leukocidins. a-toxin is a cytotoxic molecule and was one of the first secreted toxins
identified in S. aureus. This membrane damaging toxin binds to receptors on host cells,
triggering lysis and inducing a host-inflammatory response (13; 21). However, this toxin can
have different effects depending on the amount released by S. aureus. High amounts of the atoxin results in the formation of Ca2+-permissive pores, which leads to massive necrosis, while
sublytic amounts result in DNA fragmentation and eventual cell death via apoptosis (13; 22; 23).
Another group of S. aureus secreted proteins that form pores are the bicomponent leukocidins,
which include Panton-Valentine leucocidin (PVL), LukED, HlgAB, HlgCB, LukMF, and
LukAB/HG (24). The lytic activity of the bicomponent leukocidins results in the induction of
inflammation, host tissue damage, immune cell killing, and further prevents phagocytosis of S.
aureus (24; 25; 26; 27). Overall, the ability of S. aureus to release toxins further distinguishes it
as a prominent pathogen.
Another important component of S. aureus virulence is the ability of the bacterium to
release immunomodulatory proteins that further perturb host immune responses. For instance,
the release of the superoxide dismutases SodA and SodM results in the inactivation of reactive
oxygen species (28). Further, the release of the small secreted protein chemotaxis inhibitory
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protein of staphylococci (CHIPS) is important for preventing recruitment of neutrophils to the
site of infection, while the staphylococcal complement inhibitor (SCIN) is vital for inhibiting
phagocytosis of the bacteria (29; 30). Lastly, phenol-soluble modulins (PSMs), which are toxins
important for targeting red and white blood cells, are responsible for increased inflammation and
innate immune cell recruitment during infection (31). Taken together, the secretion of
immunomodulatory proteins allows S. aureus to counteract the host immune response.
A final adaptive trait that distinguishes S. aureus as a major pathogen is its ability to use
metabolites from the host for growth and survival (15). One defining example is the ability to
acquire iron from the environment (32). The majority of iron in the host is stored intracellularly,
making it inaccessible to extracellular bacteria such as S. aureus (33). Trace extracellular host
iron is not freely available and is usually found bound to high-affinity iron binding glycoproteins
such as transferrin and lactoferrin (34). In order to circumvent iron sequestration by the host, S.
aureus secretes siderophores, small molecules with even higher binding affinity for iron than the
glycoproteins produced by the host (33). As a result, S. aureus is effectively able to steal iron
from these host iron-binding proteins. The preferred iron source for S. aureus is host heme,
however, siderophores are unable to extract heme from this iron source (33). In order to acquire
iron from heme, S. aureus encodes an iron-regulated surface determinant (Isd) system, allowing
it to effectively extract iron-bound heme (35; 36; 37). Without siderophores or the Isd system to
promote iron acquisition, S. aureus would not be able to successfully infect and proliferate in the
host (36; 38)
The ability of S. aureus to suppress and evade the host immune response using a wide
array of surface adhesion proteins, toxins, and immunomodulatory proteins has certainly allowed
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it to become a successful pathogen in hospitals and the communities. Many of these virulence
factors are well-defined. However, aside from mechanisms of iron acquisition, the pathways S.
aureus uses to acquire other trace nutrients and vital cofactors in the host remains comparatively
understudied. In addition to needing trace metals for successful colonization and metabolism, S.
aureus also requires the cofactor lipoic acid, a short-chain fatty acid derivative used in the
function of multi-enzyme metabolic complexes and for maintaining redox homeostasis (15; 39).
The biosynthesis and salvage of lipoic acid is crucial for obtaining this vital cofactor and will be
the focus of this thesis.
Lipoic Acid Metabolism
Lipoic acid and Lipoylated Enzyme Complexes.
Lipoic acid, a derivative of the medium-chain fatty acid octanoic acid, is a sulfurcontaining cofactor that is covalently attached to subunits of multi-enzyme complexes needed for
one carbon metabolism (Fig 1A) (15). It is a conserved molecule and is used to maintain
metabolic flux in all domains of life. Currently, five different lipoylated enzyme complexes have
been identified in bacteria, although they are not necessarily present in all species: pyruvate
dehydrogenase (PDH), which catalyzes the oxidative decarboxylation of pyruvate to acetyl CoA;
2-oxoglutarate dehydrogenase (OGDH), which converts a-ketoglutarate to succinyl-CoA;
branched-chain 2-oxoacid dehydrogenase (BCODH), which degrades branched chain amino
acids to make a branched chain CoA intermediate needed for fatty acid biosynthesis; acetoin
dehydrogenase (AoDH), which is similar to the PDH complex and also catalyzes the conversion
of pyruvate to acetyl CoA; and the glycine cleavage system (Gcs), which catalyzes the reversible
decarboxylation of glycine (15; 39; 40). The a-ketoacid dehydrogenases are comprised of
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multiple copies of three different subunits referred to as E1, E2, and E3, whereas the glycine
cleavage system uses subunits referred to as P protein (pyridoxal phosphate-containing protein),
H protein (hydrogen carrier protein), T protein (tetrahydrofolate-containing protein), and L
protein (lipoamide dehydrogenase). The lipoic acid cofactor is attached through an amide bond
to a conserved lysine residue on the E2 subunits and acts as a swinging arm channeling
substrates through the different active sites (Fig 1B). Unlike the a-ketoacid dehydrogenase
complexes where the lipoyl group is attached to the E2 subunit, in Gcs, lipoic acid is covalently
attached to the H protein (Fig 1C) (15; 40; 41)

A.

Octanoic acid

B.

Lipoic acid
C.

Figure 1. Structure and function of lipoic acid in lipoylated enzyme complexes
A. Lipoic acid is derived from octanoic acid. Once sulfur atoms are inserted at carbons 6 and 8, the two thiols form
disulfide bonds which results in the formation of lipoic acid. B. In the Pyruvate Dehydrogenase complex, lipoic acid
is attached to the E2-subunit, which has catalytic activity and acts as a swinging arm channeling substrates to their
different active sites on E1 and E3. C. In the glycine cleavage complex, lipoic acid is attached to the H-subunit.
However, unlike the E2 subunit, the H subunit does not have catalytic activity but is able to transfer substrates to the
different active sites on the P, L, and T subunits.
Reprinted with permission from Spalding & Prigge (15) and Cronan (39) (Figure 28 – Appendix I)
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Lipoic Acid Biosynthesis and Salvage in Microbes.
The processes used to acquire lipoic acid in microbes are diverse (15; 39). Microbes such
as bacteria, fungi, and protozoa can potentially use two independent pathways to acquire lipoic
acid (39). They either generate lipoic acid through de novo biosynthesis mechanisms where the
cofactor is synthesized from an octanoic acid precursor by a lipoic acid synthetase, or by
scavenging free lipoic acid from the environment through lipoic acid salvage (42).
The first lipoic acid biosynthesis and salvage pathway was discovered in the Gramnegative bacterium Escherichia coli (Fig 2). In E. coli, the de novo biosynthesis pathway
requires two proteins: an octanoyl transferase, LipB, and a lipoic acid synthetase, LipA. Since
LipB is not very efficient at transferring free octanoic acid, it relies on the type two fatty acid
synthase to generate an octanoylated acyl carrier protein (ACP) from which it can then transfer
the octanoyl moiety onto an apo E2 subunit or H subunit (43). LipA then converts the octanoyl
domain to lipoic acid by inserting two sulfur atoms to form a dithiolane ring (44). During the
salvage pathway, E. coli uses a lipoic acid ligase, LplA, to scavenge free octanoic acid and lipoic
acid from the environment (Fig 2). The lipoic acid ligase reaction proceeds in a two-step manner:
first a tightly bound lipoyl-adenylate intermediate is formed, which is then followed by the
transfer of the lipoyl moiety onto either an apo E2 subunit such as OGDH or H subunit such as
GcvH (42; 43; 44; 45; 46; 47).
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Figure 2. Lipoic acid biosynthesis and salvage pathway of E. coli
E. coli encodes two independent pathways to acquire lipoic acid. During the de novo biosynthesis pathway, LipB, an
octanoyl transferase, transfers the octanoyl domain from an acyl carrier protein (ACP) onto the E2 subunit of aketoacid dehydrogenase complexes or the H subunit of GcvH. This octanoyl moiety is then used as a substrate for
LipA, a lipoic acid synthetase, to form a lipoyl domain. During the salvage pathway, E. coli uses the lipoic acid
ligase, LplA, to scavenge lipoic acid from the environment and ligate it onto enzyme complexes.
Reprinted with permission from Spalding & Prigge (15) (Figure 28 – Appendix I)

A more complex lipoic acid biosynthesis and salvage pathway compared to E. coli was
first discovered in the Gram-positive bacterium, Bacillus subtilis. In B. subtilis, four proteins are
required for de novo biosynthesis and salvage of lipoic acid: the octanoyl transferase, LipM;
lipoic acid synthetase, LipA; lipoyl transferase, LipL; and the lipoic acid ligase, LplJ (Fig 3)
(48). During de novo biosynthesis, B. subtilis uses LipM, which is functionally similar to E. coli
LipB, to transfer octanoic acid from an acyl carrier protein onto the H subunit of GcvH. Just like
in E. coli, LipA is then used to catalyze the formation of lipoic acid from the octanoyl moiety.
Even though LipL has the most sequence similarity with LipB, it has a very different enzymatic
activity. In B. subtilis, LipL is responsible for transferring the lipoyl moiety from the H subunit
onto additional lipoyl domains such as apo E2-PDH, apo E2-OGDH, and apo E2-BCODH (48).
During this transfer, LipL attacks the amide linkage whereas LipM and LipB attack the thioester
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bond when transferring the octanoyl moiety. In addition, the LipL reaction is completely
reversible indicating that the lipoyl moiety can be transferred among different E2 subunits (39).
Just like E. coli, B. subtilis encodes a single lipoic acid ligase, LplJ, responsible for scavenging
lipoic acid from the environment and lipoylating various enzyme complexes such as PDH,
OGDH, and BCODH (48).

LipM
LplJ

LplJ

LipL

Figure 3. Lipoic acid biosynthesis and salvage pathway of B. subtilis
Similar to E. coli, B. subtilis is able to synthesize and scavenge lipoic acid. However, B. subtilis uses a
octanoyltransferase, LipM, to transfer the octanoyl moiety to the E2 subunit. From there, LipA converts the octanoyl
moiety to lipoic acid. Then, LipL transfers the lipoyl moiety onto different enzyme complexes. In the salvage
pathway, B. subtilis uses the LplJ ligase to scavenge lipoic acid from the environment.
Reprinted with permission from Spalding & Prigge (15). (Figure 28 – Appendix I)

The lipoic acid biosynthesis and salvage pathways of E. coli and B. subtilis are the most
characterized and well-understood pathways to date. However, lipoic acid metabolism can be
found in numerous organisms with varying degrees of complexity. The comparison of
Helicobacter pylori and Pseudomonas aeruginosa is one example in Gram-negative bacteria that
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highlights the diversity of lipoic acid acquisition strategies in microorganisms. Unlike many
other bacteria, H. pylori does not encode the lipoylated enzyme complexes nor the enzymes
needed for lipoic acid biosynthesis and salvage. Instead, H. pylori uses anaerobic and
microaerophilic alternatives such as a-ketoglutarate oxidoreductase (KOR) as an alternative to
OGDH and pyruvate:flavodoxin oxireductase (POR) as an alternative to PDH to maintain a
functional TCA cycle (49; 50; 51; 52). P. aeruginosa on the other hand, has both the de novo
biosynthesis and salvage enzymes and encodes all five known lipoylated enzyme complexes
(15).
Gram-positive bacteria, which include the Firmicutes phylum, display a similar level of
diversity in lipoic acid metabolism. In contrast to other bacteria, members of the Firmicutes
phylum often encode multiple ligases needed to scavenge lipoic acid, however they do not
always encode the enzymes necessary for de novo biosynthesis (15). Listeria monocytogenes for
instance, does not encode the enzymes needed for de novo biosynthesis, rather it uses two lipoic
acid ligases, LplA1 and LplA2, and a lipoylamidotransferase, LipL, to scavenge lipoic acid from
environmental sources (53; 54). Recent studies have shown that LplA1 is largely responsible for
scavenging lipoic acid and modifying the glycine cleavage system subunit, GcvH. In addition, L.
monocytogenes was found to have lipoamidase activity, which may be responsible for cleaving
the amide bond linking lipoic acid to its conserved lysine residue, subsequently allowing LplA1
to acquire the lipoyl domain from host derived lipoyl peptides (55) (Fig 4). Unlike L.
monocytogenes, bacteria belonging to Bacillales often encode multiple ligases, but may also
encode enzymes required for the de novo biosynthesis pathway such as LipA, the lipoic acid
synthetase described earlier for B. subtilis (15).
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Figure 4. Model of lipoic acid ligase activity in L. monocytogenes
In L. monocytogenes, the lipoamidase (Lpd) is important for cleaving lipoic acid off of a lipoylated peptide allowing
LplA1 to scavenge the lipoyl domain and attach it to the H-subunit of the Gcs. Subsequently, LipL is able to transfer
the lipoyl moiety to different E2 subunits.
Reprinted with permission from Christensen et al. (55) (Figure 28 – Appendix I)

In contrast to bacteria, where lipoic acid biosynthesis occurs in the cytosol, lipoic acid
metabolism in fungi is localized in the mitochondria. Yeasts such as Saccharomyces cerevisiae
and Candida albicans only encode three enzymes (Lip2, Lip3, Lip5) that are used to lipoylate
OGDH, GcvH, and PDH (56; 57; 58). Lip2 and Lip5 are orthologs of the E. coli LipB and LipA
enzymes respectively, and are responsible for de novo biosynthesis. Even though the yeast
encodes a lipoic acid ligase, Lip3, it is not able to scavenge lipoic acid. Current literature
suggests that disruption of both lip2 and lip5 in the presence of a functional lip3 renders the yeast
incapable of growing in medium supplemented with lipoic acid (59; 60). These data imply that
yeast solely depend upon the de novo biosynthesis pathway for the acquisition of lipoic acid, or
that lip3 may not be expressed under the experimental conditions used in prior studies.
In protozoans, specifically apicomplexans, lipoic acid metabolism can be found in both
the mitochondria and apicoplasts (61; 62). To date, the acquisition of lipoic acid in protozoans
has been best characterized in the pathogenic Plasmodium falciparum and Toxoplama gondii.
Both P. falciparum and T. gondii are capable of lipoylating four of the five known lipoylated

12
enzyme complexes: PDH, OGDH, BCODH, and GcvH. Interestingly, the lipoylated complexes
OGDH, BCODH, and GcvH are localized in the mitochondria, whereas PDH is found in the
apicoplast. Furthermore, lipoylation of the enzyme complexes occurs strictly during the blood
stage of the parasitic lifecycle and is divided into the two different organelles (63). Lipoic acid
de novo biosynthesis occurs in the apicoplast with the help of the E. coli orthologs LipA and
LipB, whereas lipoic acid salvage occurs in the mitochondria with the help of two lipoic acid
ligases (62; 64; 65). Both of the apicomplexans are known to cause severe disease in humans and
it has been suggested that lipoic acid metabolism may play a role in promoting pathogenicity.
In summary, lipoic acid is a conserved molecule, however the acquisition of lipoic acid is
very diverse among bacteria, fungi, and protozoans. Many of these organisms encode either a de
novo biosynthesis pathway, salvage pathway, or both thereby conferring a range of complexities
that may have evolved to satisfy the unique nutrient requirements of that particular organism.
Lipoic acid metabolism can be found in several organelles of eukaryotes, further implying that
each organism has adapted the pathway that best suits its lifestyle. Important to the work in this
thesis, these adaptations appear to be beneficial to the pathogenic lifestyle of some bacteria.
Lipoic Acid Biosynthesis and Salvage in Pathogenic Bacteria and Parasitic Microbes.
A small body of literature exists that suggests lipoic acid metabolism can have a major
role in facilitating optimal pathogenesis in microorganisms (15; 66; 67; 68; 69; 70). It has been
shown that lipoic acid salvage in parasites such as P. falciparum, the causative agent of malaria,
is crucial for the survival and growth of the parasite at the blood-stage (15; 67). In addition,
disruption of the lipoic acid biosynthesis and salvage pathway can lead to attenuation of
Burkholderia pseudomallei virulence in an intranasal mouse infection model. In P. aeruginosa, a
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functional lipoylated PDH enzyme complex has been shown to be important for the expression
of the type three secretion system (T3SS) (15; 66; 68). Furthermore, disruption of dlaT, a gene
encoding the E2 PDH subunit in M. tuberculosis, results in increased susceptibility to
macrophage killing and oxidative stress (15; 69; 70).
As mentioned previously, L. monocytogenes, a prominent pathogen responsible for
foodborne illnesses, has two lipoic acid ligases, LplA1 and LplA2. It has been demonstrated that
both ligases have ligase activity in vitro. However, LplA2 activity could only be demonstrated in
vitro when the medium was supplemented with a surplus of free lipoic acid. LplA1, on the other
hand, stimulated bacterial growth with low concentrations of peptide bound lipoic acid, but not
when the medium was supplemented with free lipoic acid. During in vivo mouse infections, only
LplA1 contributed to bacterial replication, indicating LplA2 activity is dispensable during
intracellular growth. This is yet another example of how divergent functions of lipoic acid
acquisition can promote survival within a nutrient limited niche. Overall, the ability of pathogens
such as L. monocytogenes, to acquire lipoic acid through biosynthesis and/or salvage is a
defining characteristic required for survival during host infection.
Lipoic Acid De Novo Biosynthesis and Salvage in S. aureus.
S. aureus, another prominent pathogen and member of the Firmicutes phylum like B.
subtilis and L. monocytogenes, also harbors genes for lipoic acid metabolism. S. aureus has one
of the most complicated lipoic acid biosynthesis and salvage pathways. It encodes the three
enzymes of de novo biosynthesis LipM, LipA, and LipL along with two lipoic acid ligases
LplA1 and LplA2. In addition, S. aureus encodes two GcvH proteins, which may be used to
transfer lipoic acid onto different E2 subunits (15; 48; 71; 72). Just like B. subtilis, S. aureus
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encodes an octanoyl transferase, LipM, which transfers an octanoyl moiety from the ACP to
GcvH; and a lipoyl synthetase, LipA, which then converts the octanoyl moiety to lipoic acid. In
the last step of the de novo biosynthesis pathway, it is hypothesized that LipL then transfers the
lipoyl domain from GcvH onto PDH, BCODH, and OGDH. Like L. monocytogenes, S. aureus
also encodes two lipoic acid ligases, LplA1 and LplA2, responsible for scavenging lipoic acid
from the environment (Fig 5).

Figure 5. Lipoic acid biosynthesis and salvage pathway of S. aureus
S. aureus can acquire lipoic acid through the lipoic acid biosynthesis and salvage pathway. LipM, LipA, and LipL
are enzymes involved in lipoic acid biosynthesis. LipM, an octanoyl transferase, transfers octanoic acid from an acyl
carrier protein to GcvH. LipA, a lipoic acid synthetase, converts octanoic acid to lipoic acid. LipL, a transferase,
transfers the lipoic acid onto the E2 subunits of other enzyme complexes such as OGDH, PDH, and BCODH. In the
lipoic acid salvage pathway, LplA1, a lipoic acid ligase, salvages lipoic acid from the environment and attaches it to
the E2 subunits of OGDH or GcvH. Currently the function of LplA2 is not well characterized but it is thought that
LplA2 attaches lipoic acid to GcvH-L during oxidative stress.
Reprinted with permission from Zorzoli et al. (71)

LplA1, a Lipoic Acid Ligase in S. aureus, is Crucial for Lipoic Acid Salvage In Vitro.
A unique feature of the S. aureus de novo biosynthesis and salvage pathways is that,
unlike B. subtilis and many of the other pathogenic Firmicutes, S. aureus encodes two lipoic acid
ligases, LplA1 and LplA2 in addition to its de novo biosynthesis enzymes (15; 48; 72). Just like
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S. aureus, L. monocytogenes also encodes two lipoic acid ligases, where it was found that LplA1
uses host derived-lipoyl peptides whereas LplA2 uses free lipoic acid. Based on this information,
it was hypothesized that LplA1 and LplA2 in S. aureus have distinct functions that facilitate
important acquisition activities in vitro and in vivo. To test this hypothesis, a former member of
the Alonzo laboratory, Azul Zorzoli, generated a set of lipoic acid ligase mutants in a ΔlipA
mutant background in order to block de novo biosynthesis of lipoic acid and directly assess
salvage activity without confounding outcomes associated with de novo biosynthesis. Azul
conducted growth curves in Roswell Park Memorial Institute medium (RPMI), RPMI
supplemented with branched chain fatty acids (BCFA) to bypass the requirement of lipoic acid,
or either base medium (RPMI or RPMI+BCFA) supplemented with lipoic acid or octanoic acid.
She found that all strains with a ΔlipA mutation were unable to grow in the absence of
supplements (Fig 6A). The same growth pattern was observed when RPMI was supplemented
with octanoic acid (Fig 6B). However, when supplemented with lipoic acid, all strains grew
similar to the WT strain, except the ΔlipAΔlplA1 double mutant, which was unable to replicate
(Fig 6C) (71). Azul’s data suggested that only LplA1 is required for lipoic acid salvage in vitro,
while the role of LplA2 in lipoic acid salvage remained unknown.
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Figure 6. LplA1 facilitates lipoic acid salvage in vitro
Growth assessment of lipoic acid ligase in-frame deletion mutants in the background of a DlipA mutant. A. Growth
curve in RPMI with no supplementation (RPMI). B. Growth curve in RPMI supplemented with octanoic acid
(RPMI+OA). C. Growth curve in RPMI supplemented with lipoic acid (RPMI+LA).
Reprinted with permission from Zorzoli et al. (71)

Either of the Two Lipoic Acid Ligases, LplA1 and LplA2, are Sufficient to Promote
Infection of the Kidneys During Murine Systemic Infection.
Since LplA2 did not have an apparent role in S. aureus lipoic acid salvage in vitro, it was
hypothesized that it might not be functional under the conditions tested. It was reasoned that
LplA2 might play a role in facilitating lipoic acid use in alternative environments where free
lipoic acid is restricted, such as in mammalian tissues. In order to evaluate the ability of LplA1
and LplA2 to promote bacterial survival in mammalian tissues, mice were infected with WT,
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ΔlipAΔlplA1ΔlplA2, ΔlipAΔlplA1ΔlplA2+lplA1, and ΔlipAΔlplA1ΔlplA2+lplA2 strains. In
animals infected with a ΔlipAΔlplA1ΔlplA2 mutant, which lacks a functional de novo
biosynthesis and salvage pathway, a severe decrease in bacterial burden was observed. However,
when infected with strains expressing either LplA1 or LplA2 in single copy from constitutive
promoters, ΔlipAΔlplA1ΔlplA2+lplA1 and ΔlipAΔlplA1ΔlplA2+lplA2, mice had similar colony
forming units (CFU) in the kidney when compared to the WT strain. These data imply that the
salvage pathway is crucial for bacterial replication in the kidneys and that either LplA1 or LplA2

log10 CFU/Organ

is sufficient to promote lipoic acid acquisition in the kidneys.

Figure 7. LplA1 and LplA2 are important for lipoic acid salvage in vivo
In a murine S. aureus bloodstream infection model, bacterial burden (CFU/organ) was determined in the kidney 96
hours post infection after infecting mice with 1X107 CFU of WT (N=21), ΔlipAΔlplA1ΔlplA2 (N=20),
ΔlipAΔlplA1ΔlplA2+lplA1 (N=14), and ΔlipAΔlplA1ΔlplA2+lplA2 (N=15) strains. Compared to WT,
ΔlipAΔlplA1ΔlplA2+lplA1, and ΔlipAΔlplA1ΔlplA2+lplA2, a ΔlipAΔlplA1ΔlplA2 strain had significantly decreased
bacterial burden. Log10CFU/organ is displayed for each mouse infected, along with the median as a measure of
central tendency – red line. Statistics were determined using nonparametric 1-way ANOVA with Kruskal-Wallis
multiple comparisons post-test to evaluate statistical significance. Statistical significant differences are indicated by
****, P<0.0001; and ***, P<0.001.
Reprinted with permission from Zorzoli et al. (71)
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Concluding Remarks
S. aureus is a prominent pathogen that uses myriad virulence factors to establish itself in
the host. One of the lesser studied traits that enhances S. aureus colonization in the host is the
ability to acquire lipoic acid from nutrient deficient environments. Our lab’s previous studies
have characterized the lipoic acid biosynthesis and salvage pathway of S. aureus using a genetic
approach and murine systemic infection models. It was determined that only LplA1 is sufficient
for bacterial growth in vitro, whereas both ligases are sufficient for lipoic acid acquisition during
infection. However, the exact activities of the two lipoic acid ligases, LplA1 and LplA2, have yet
to be fully elucidated. Though limited information exists in the literature, work in L.
monocytogenes suggests that bacteria with multiple ligases likely use these enzymes to acquire
the cofactor in distinct ways. In addition, the lplA2 gene in S. aureus is encoded in an operon that
is upregulated under oxidative stress conditions, suggesting that lplA2 expression may be
upregulated in vivo where oxidative stress to the bacterium is presumed to be high (72). Based
on this information, I hypothesized that LplA1 and LplA2 in S. aureus stimulate growth by using
alternative lipoylated substrates and/or that lplA2 gene expression is induced during infection,
providing S. aureus with tremendous opportunity to adapt in the face of nutrient paucity. To test
this hypothesis, I (i) conducted growth curves to evaluate the ability of the ligases to use
alternative lipoyl substrates and (ii) purified the proteins of the de novo biosynthesis and salvage
pathway along with apo E2/H subunits of lipoylated enzyme complexes to directly assess the
ability of either ligase to lipoylate the known lipoylated enzyme complexes of S. aureus.
Characterizing the mechanisms of lipoic acid salvage in S. aureus will be instrumental to
understanding the ability of this bacterium to colonize and proliferate in diverse nutrient limited
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environments, including host tissue, and may help in the development of new therapeutics to
combat S. aureus infections.

CHAPTER TWO
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
All bacterial strains used in this manuscript are listed in Table 1. E. coli strains were
routinely grown in Lysogeny Broth (LB) (Amresco) with antibiotics added as necessary. S.
aureus strains were grown in either rich medium, Tryptic Soy Broth (TSB) (Criterion), or in
defined medium, Roswell Park Memorial Institute medium (RPMI) (Corning) supplemented
with 1% casamino acids (Amresco). All strains were grown overnight at 37°C at a 45° angle,
shaking at 220 rpm unless stated otherwise. For growth curves, S. aureus overnight cultures were
grown in RPMI containing branched chain carboxylic acids (10.8 mM isobutyric acid, 9.2 mM
2-methylbutyric acid, 9 mM isovaleric acid, and 10 mM sodium acetate) (Sigma) in order to
bypass the requirement of lipoic acid or octanoic acid. When needed, cultures were
supplemented with the following concentrations of antibiotics; 100 µg/ml of ampicillin (AMP), 3
µg/ml of erythromycin (ERM), 10 µg/ml of chloramphenicol (CM), and 1 µg/ml of anhydrous
tetracycline (ANTET).
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Table 1. List of Strains
Designation

Description

Strain
USA300 LAC

DlipA
DlipADlplA1

S. aureus USA300 Strain LAC. Plasmid cured.
E. coli strain used for propagating pIMAY in S.
aureus
Restriction deficient S. aureus for plasmid
propagation
LAC with in-frame deletion of lipA
LAC with in-frame deletion of lipA and lplA1

DlipADlplA2

LAC with in-frame deletion of lipA and lplA2

FA-S1180

DlipADlplA1DlplA2

LAC with in-frame deletion of lipA, lplA1 and
lplA2
LAC with in-frame deletion of lipA, lplA1 and
lplA2, complemented with pJC1111-lplA1
LAC with in-frame deletion of lipA, lplA1 and
lplA2, complemented with pJC1111-lplA1
LAC with in-frame deletion of lipA, lipL,
lplA1, and lplA2
pOS1-PlplA2(L)-gfp - gfp promoter fusion (long 300 bp) plasmid transformed into DlipADlplA1
pOS1-PlplA2(L)-gfp - gfp promoter fusion (long 300 bp) plasmid transformed into DlipMDlplA1
pOS1-PlplA2(S)-gfp - gfp promoter fusion (short 100bp) plasmid transformed into DlipADlplA1
pOS1-PlplA2(L)-gfp - gfp promoter fusion (short 100 bp) plasmid transformed into DlipMDlplA1
pET15b encoding 6x-His-GcvH transformed
into ΔlipA::kan LysY IQ E. coli
pET15b encoding 6x-His-GcvH-L transformed
into ΔlipA::kan LysY IQ E. coli
pET15b encoding 6x-His-OGDH transformed
into ΔlipA::kan LysY IQ E. coli
pET15b encoding 6x-His-PDH transformed
into ΔlipA::kan LysY IQ E. coli
pET15b encoding 6x-His-BCODH transformed
into ΔlipA::kan LysY IQ E. coli
pET15b encoding 6x-His-LipM transformed
into LysY IQ E. coli
pET15b encoding 6x-His-LipA transformed
into LysY IQ E. coli

FA-S1178

6x-His-LipL

pET15b encoding 6x-His-LipL transformed
into LysY IQ E. coli

FA-S1277

6x-His-LplA1

pET15b encoding 6x-His-LplA1 transformed
into LysY IQ E. coli

FA-S1284

6x-His-LplA2

pET15b encoding 6x-His-LplA2 transformed
into LysY IQ E. coli

FA-S1278

WT LAC
DH5a
RN4220

DlipADlplA1DlplA2 + lplA1
DlipADlplA1DlplA2 + lplA2
DlipADlplA1DlplA2DlipL
DlipADlplA1 + pOS1-PlplA2(L)-gfp
DlipMDlplA1 + pOS1-PlplA2(L)-gfp
DlipADlplA1 + pOS1-PlplA2(S)-gfp
DlipMDlplA1 + pOS1-PlplA2(S)-gfp
6x-His-GcvH
6x-His-GcvH-L
6x-His-OGDH
6x-His-PDH
6x-His-BCODH
6x-His-LipM
6x-His-LipA

RN4220
FA-S831
FA-S1249

FA-S1200
FA-S1212
FA-S1319
FA-S1369
FA-S1391
FA-S1393
FA-S1395
FA-S1357
FA-S1383
FA-S1363
FA-S1359
FA-S1367
FA-S1276
FA-S1283

22
Molecular Genetic Techniques
Chromosomal DNA was isolated from S. aureus using the Wizard Genomic DNA
purification kit (Promega) following the manufacturers protocol with minor modifications.
Overnight cultures were started in 5 ml TSB and 1.5 ml was spun down the next day at 15,000
rpm for 3 min. Bacterial pellets were resuspended in 200 µl of TSM (50 mM Tris, 0.5 M
Sucrose, 10 mM MgCl2, pH 7.5). In order to disrupt the cell wall, 2.5 µl of lysostaphin (2 mg/ml
in 0.5 Tris, pH 8.0) was added to the resuspended cell pellet and incubated for 15 min at 37°C.
Following incubation, the bacteria were pelleted at 15,000 rpm for 3 min and the supernatant was
discarded. The remaining steps to purify genomic DNA from S. aureus were completed using the
manufacturers protocol. Recombinant plasmids were extracted using QIAGEN mini and midi
prep kits with the following modifications for plasmid isolation from S. aureus. An overnight
culture of S. aureus was grown in 5 ml TSB and pelleted at 4000 rpm for 10 min the following
day. The bacterial pellet was resuspended in 400 µl TSM (50 mM Tris, pH 7.5, 0.5 Sucrose, 10
mM MgCl2) followed by the addition of 20 µl of lysostaphin. This mixture was incubated for 10
min at 37°C to break down the cell wall and then spun down at 13,000 rpm for 2 min after which
the supernatant was discarded. The following steps were completed as suggested by the
manufactures protocol. Polymerase chain reaction (PCR) products were either gel extracted or
purified using QIAGEN QIAquick gel extraction and PCR purification kits. All PCRs were
conducted using Phusion High-Fidelity DNA polymerase (New England Biolabs).
E. coli Competent Cell Preparation
An overnight culture of E. coli was grown in 3 ml LB at 37°C with shaking at 180 rpm.
The next day, the bacteria were subcultured 1:55 into a 250 ml flask and grown for an additional
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~2.5 hours at 37°C shaking at 180 rpm until the culture reached an optical density at 600 nm
(OD600) of 0.3-0.4. The following steps were all completed on ice. Cultures were aliquoted into
50 ml tubes and chilled on ice for 10 min. Afterwards they were spun down at 4000 rpm for 10
min and the bacterial pellet was resuspended in TFB-1 (20 mM KOAc, 100 mM RbCl2, 10 mM
CaCl2, 50 mM MnCl2, 15% glycerol, adjusted to pH 5.8 using 0.2 M Acetic acid) and incubated
on ice for an additional 10 min. Bacteria were then pelleted at 4000 rpm for 10 min and the
bacterial pellet was resuspended in 1/25 of the original culture volume in TFB-2 (10 mM MOPS,
75 mM CaCl2, 10 mM RbCl2, 15% glycerol, adjusted to pH 6.5 using KOH). 100 µl of the
competent cells were aliquoted into Eppendorf tubes and stored at -80°C.
E. coli Heat Transformation
In order to transform competent E. coli, 5 µl of ligation mix or 1 µl of purified plasmid
was added to 50 ul of competent E. coli. This reaction mixture was incubated on ice for 30 min,
heat shocked at 42°C for 45 seconds, and then incubated for 2 min on ice. Following the
incubation, 250 µl of SOC medium was added and the bacteria were incubated for 2 hours at
37°C shaking at 220 rpm. Subsequently, 100 µl of the bacteria was plated on LB agar plates
containing the antibiotic needed to select for plasmid transformants.
Preparation of S. aureus Electrocompetent Cells
An overnight culture of S. aureus was grown in 5 ml TSB at 37°C shaking at 220 rpm.
The following day the bacteria were subcultured 1:100 in 30 ml TSB and incubated for an
additional 3 hours at 37°C until the culture reached an OD600 of 0.5. The bacterial culture was
spun down for 10 min at 8000 rpm to pellet the bacteria. All subsequent steps from here were
carried out on ice. After the bacteria were spun down, the pellet was washed by resuspending it
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in 30 ml ice cold 10% glycerol and spun down again for 10 min at 8000 rpm. These wash steps
were repeated three times. After the last wash, the bacteria were resuspended in 3 ml 10%
glycerol, aliquoted into Eppendorf tubes, and stored at -80°C.
S. aureus Transformation via Electroporation
Frozen competent cells were thawed at room temperature for 5 min. 2 µl of plasmid DNA
was then added to 50 µl of S. aureus RN4220 or LAC competent cells and incubated at room
temperature for 30 min. The competent cell mixture was transferred to sterile 2 mm
electroporation cuvettes and pulsed at 1800 V, 10 µF, and 600 W. After electroporation, the
bacteria were resuspended in 750 µl of TSB or TSB+BCFA and incubated at 37°C or 30°C for
1.5 hours to allow the bacteria to recover. After the incubation, the bacteria were pelleted at
10000 rpm for 2 min and resuspended in 100 µl of TSB or TSB+BCFA, plated on
TSA/TSA+BCFA plates containing antibiotic and incubated at 37°C or 30°C for 1-2 days.
Generation of In-Frame Deletion Mutants
Regions of homology corresponding 500 bp upstream and 500 bp downstream of genes
lplA1 and lipA were amplified using primer pairs 0930 SOE1/SOE2 and 0930 SOE3/SOE4 and
0829 SOE1/SOE2 and 0829 SOE3/SOE4 (Table 2) and PCR purified using the QIAGEN PCR
clean-up kit. The upstream and downstream amplicons from these PCRs were used as template
in a splicing by overlap extension (SOEing) reaction with primers 0930 SOE1/0930 SOE4 and
0829 SOE1/0829 SOE4 to generate the amplicon used in the subsequent mutagenesis. The two
amplicons of 0829 and 0930 were then cloned individually into the allelic replacement plasmid,
pIMAY, which contains a chloramphenicol resistance marker using KpnI and SacI restriction
endonucleases. The pIMAY-lplA1(0930) mutagenesis plasmid was introduced into a DlipM
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lplA1::erm S. aureus mutant and the pIMAY-lipA (0829) mutagenesis plasmid was introduced
into a DlplA1 lipA::erm S. aureus mutant strain by electroporation and grown overnight at 30°C
in the presence of chloramphenicol. The DlipM lplA1::erm and DlplA1 lipA::erm S. aureus
mutants containing the pIMAY-lplA1 and pIMAY-lipA mutagenesis plasmid respectively were
cultured at 37°C in the presence of chloramphenicol. pIMAY is unable to replicate at 37°C and
as a result it is forced to integrate into the S. aureus genome at the region of homology upstream
or downstream of lplA1 and lipA. To facilitate a second homologous recombination event,
cultures were grown at 28°C without chloramphenicol to allow for plasmid replication resulting
in the excision of the plasmid from the S. aureus genome and generation of a clean deletion. To
cure mutant strains of the pIMAY plasmid, bacteria were plated on agar plates containing
anhydrous tetracycline (AnTet). Lastly, colonies were screened for chloramphenicol-sensitivity
and clean deletion mutants DlipA DlplA1 and DlipM DlplA1 were confirmed via PCR
amplification of the desired target region using primers 0829 SOE1/4, 0930 SOE1/4, and 1494
SOE1/4 (Table 2).
Bacteriophage Mediated Transduction
All transductions in S. aureus were conducted with phage f11. In order to package the
phage with donor DNA, a 3 ml overnight culture of the marked donor strain (DlipL::kan) was
started in TSB/LB (1:1) supplemented with 5 mM CaCl2 and 5 mM MgSO4 and grown overnight
shaking at 37°C. The following day, the overnight strain was subcultured 1:100 into 10 ml
TSB/LB (1:1) supplemented with 5 mM CaCl2 and 5 mM MgSO4 and grown for ~2.5 hours
shaking at 37°C until the culture reached an OD 600 of 0.3 to 0.9. 500 µl of the bacterial culture
was incubated with 10-fold serial dilutions of f11 phage stock in TMG (10 mM Tris pH 7.5, 5
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mM MgCl2, 0.01% gelatin (v/v)), vortexed gently, and incubated at room temperature for 30
minutes. After 30 minutes, tubes containing the bacteria and phage dilutions were mixed with 3
ml CY Top agar (Casamino acids 3g/L, Yeast Extract 3g/L, NaCl 6g/L, 7.5 g/L agar, +/- BCFA
as needed) supplemented with 5 mM CaCl2 and 5 mM MgSO4, cooled to 55°C, and poured onto
TSA plates. After the top agar solidified, plates were incubated at 30°C overnight. The next day
the top agar from 2-3 plates with confluent plaques was scraped off the plate using a sterile
scoopula and resuspended in 2ml of TMG buffer per plate followed by extensive vortexing. The
tubes were then spun down at 13,000 rpm for 15 minutes. The supernatant was filtered twice
using a 0.2 µm filter and then an additional two times with a 0.45 µm filter. All packaged phage
stocks are kept at 4°C.
To transduce marked mutations, the recipient strain (DlipA DlplA1 DlplA2) was grown
overnight with shaking at 37°C in 20 ml TSB+BCFA/LB (1:1) supplemented with 5 mM CaCl2.
The following day, the recipient strain was spun down at 13,000 rpm for 15 min and resuspended
in 3 ml of TSB+BCFA/LB (1:1) supplemented with 5 mM CaCl2. 500 µl of the recipient bacteria
were serial diluted and incubated with 100 µl of the packaged f11 phage (108-109 PFU) or 100 µl
of TMG buffer as an uninfected control for 30 min at room temperature, inverting the tubes
every 10 min. After 30 min the bacterial/phage suspension was supplemented with 40 mM
NaCitrate and incubated for an additional 30 min, inverting the tubes every 10 min. The tubes
were spun down at 13,000 rpm for 3 min and washed twice with 500 µl TSB+BCFA/LB (1:1)
supplemented with 10 mM NaCitrate. Washed bacterial pellets were resuspended with 250 µl of
TSB+BCFA/LB (1:1) supplemented with 10 mM NaCitrate and 200 µl was plated out on
TSB+BCFA containing 10 mM NaCitrate and the respective antibiotic of interest. Plates were
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incubated at 37°C for 24-48 hours until bacterial colonies were detected. All mutants were
verified using PCR and their respective primers.
Table 2. List of Primers
Name
0328NC-F
0328N-R
0571NC-F
0571N-R
0930NC-F
0930N-R
0829NC-F
0829N-R
1494NC-F
1494N-R
GcvH-L NC-F
GcvH-L N-R
gfp1720-25F short
gfp1715/20-25R short/long
gfp1715-25F long
791hisN/C-F791hisN-R
995hisN/C-F
995hisN-R1305hisN/C-F1305hisN-R
1464hisN/C-F
1464hisN-R
0930 SOE1
0930 SOE2
0930 SOE3
0930 SOE4
0829 SOE1
0829 SOE2
0829 SOE3
0829 SOE4
1494 SOE1
1494 SOE4

Sequence
ATAT-CATATG(NdeI)-TACTTAATAGAACCGATTAG
ATAT-GGATCC(BamHI)-TTAACTTAAAATCATATCCAC
ATAT-CATATG(NdeI)-CAATCTTTCGCATTCGATG
ATAT-GGATCC(BamHI)-CTATTGCATTTGATCTATCAT
ATAT-CATATG(NdeI)-AAATTCATTAGTAATAATAATATT
ATAT-GGATCC(BamHI)-TTATGACATTAATCTAATTAATT
ATAT-CATATG(NdeI)-GCGACAAAAAACGAGGAAA
ATAT-GGATCC(BamHI)-TTAACTATTTAACTGTGCCT
ATAT-CATATG(NdeI)-ACTGAAACTTGGAATTTTATT
ATAT-GGATCC(BamHI)-CTACTTTCTAAACATCCATT
ATAT- CATATG (NdeI)-AAAAAGTTAGCCAATTATTTAT
ATAT- GGATCC(BamHI)-TTAAGCCTCCGGTAATGC
ATAT-CTGCAG(PstI)-AAGTTAATTGAAAAACGTTATC
ATAT-GGTACC(KpnI)-TCCGTCATCTCCAAACTTA
ATAT-CTGCAG(PstI)-ACTATGATTCCTTTTCTATTC
ATAT-CATATG(NdeI)-GCAGTACCAAATGAATTGAA
ATAT-GGATCC(BamHI)-TTATTCACCAATCATTTCTGA
ATAT-CATATG(NdeI)-GCATTTGAATTTAGATTACCC
ATAT-GGATCC(BamHI)-TTACCCCTCCATTAATAATAA
ATAT-CATATG(NdeI)-CCAGAGGTTAAAGTTCCAG
ATAT-GGATCC(BamHI)-TTAAGATTCTAATAATAAGTCTT
ATAT-CATATG(NdeI)-GAAATAACAATGCCTAAGTTA
ATAT-GGATCC(BamHI)-CTAATATATATTTGTATTTTCTAA
CCC-GGTACC(KpnI)-GCATTATACCTGTATAAATAC
ATAGTCCTTTAATCGTTTATGA-GGCGCC(KasI)TTTCATTACAATCTCTCCCTT
AAGGGAGAGATTGTAATGAAA-GGCGCC(KasI)TCATAAACGATTAAAGGACTAT
CCC-GAGCTC(SacI)-ATAAGCAAAACCTCGCTTTAT
CCC-GGTACC(KpnI)-GCACAATGTGCCATCATCAA
CCTTATTAATGGTTAAATATTAACT-GGCGCC(KasI)CGCCATAACAACACATACCC
GGGTATGTGTTGTTATGGCG-GGCGCC(KasI)AGTTAATATTTAACCATTAATAAGG
CCC-GAGCTC(SacI)-ATTAATGTTCAGTATCTTGAATG
CCC-GGTACC(KpnI)-TTATAGCCGCCTTTTAACATA
CCC-GAGCTC(SacI)-ATATTCAAAGTGCTCACACTT
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Preparation of Proteinase K Agarose Beads and Digestion of OGDH and PDH from
Porcine Heart
Proteinase K agarose beads, pyruvate dehydrogenase (PDH), and 2-oxoglutarate
dehydrogenase (OGDH) were purchased from Sigma. The Proteinase K beads were activated by
resuspending 40 mg beads in 1 ml activation buffer (20 mM Tris-HCl, 1 mM CaCl2, pH 7.4) and
incubating for 2 hours at room temperature. Before protein digestion, the beads were spun down
for 3 min at 2000 rpm and resuspended in 800 µl 20 mM Tris-HCl, 1 mM CaCl2, pH 7.4. This
step was repeated three times. Stocks of both PDH (15.9 mg/ml) and OGDH (7 mg/ml) were
buffer exchanged into 20 mM Tris-HCl, 1 mM CaCl2 pH 7.4 by taking 2 ml of the stock
solutions and diluting them into 100 ml of 20 mM Tris-HCl, 1 mM CaCl2 pH 7.4 followed by
concentration with 10 kDa cut-off Amicon Ultra-15 spin columns (Milipore). Subsequently, 2.5
mg/ml PDH and 1.16 mg/ml OGDH were digested overnight with 400 µl of the Proteinase K
agarose beads. The following morning, the digestion reaction was spun down at 13,000 rpm for
10 min to pellet the agarose beads and the supernatant was used for subsequent growth curves.
Growth Curves
Overnight cultures were grown in 200 µl of RPMI + BCFA in a 96-well plate shaking at
220 rpm at 37°C. The next day, the strains were pelleted for 10 min at 3700 rpm at 4°C. The
strains were washed three times with 200 µl of RPMI alone in order to remove any remaining
BCFA that might stimulate growth. Each strain was grown in RPMI supplemented with 48 µM
lipoic acid (Sigma), 48 µM lipoamide (Sigma), 1.16 mg/ml OGDH (Sigma) or proteinase K
digested OGDH, 2.5 mg/ml PDH (Sigma) or proteinase K digested PDH, 48 µM octanoic acid
(Sigma), and 100 µM DKLA or 100 µM DKA tripeptides (Anaspec). All growth curves were
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conducted in a 96-well plate at 37°C over a 10-hour period to allow the bacterial strains to reach
stationary phase. Bacterial replication was monitored every hour by measuring OD at 550 nm on
a BioTek plate reader.
Generation of PlplA2-gfp Transcriptional Reporter Fusions
Based on annotations from the genome sequence of S. aureus FPR3757 USA300, lplA2 is
the last gene in an operon that encodes four additional genes; LLM, gcvH-L, macro, and sirTM.
The predicted promoter region of lplA2 lies approximately four genes upstream of the lplA2 open
reading frame. Since the predicted lplA2 promoter region and its regulatory elements are
unknown and a small putative gene (SAUSA300_0323) exists approximately 100 bp upstream of
LLM, regions 100 bp and 300 bp upstream of LLM were amplified in order to generate
transcriptional reporters that fuse the predicted promoter region of lplA2 to gfp. Primers gfp
1720-25F, and gfp 1715/20-25R were used to amplify the 100 bp regions, whereas primers gfp
1715-25F and gfp 1715/20-25R were used to amplify the 300 bp region (Table 2). Both the 100
bp and 300 bp predicted promoter regions were subcloned upstream of the gfp gene in plasmid
pOS1 using PstI and KpnI restriction endonucleases and subsequently transformed into DH5a E.
coli. Both reporter constructs were then transformed via electroporation into DlipADlplA1 and
DlipMDlplA1 S. aureus strains.
Generation of 6x-Histidine Tagged Protein Expression Plasmids
In order to purify proteins of the lipoic acid biosynthesis and salvage pathway (LipM,
LipA, LipL, LplA1, and LplA2) as well as non-lipoylated E2-subunits of PDH, OGDH,
BCODH, and non-lipoylated H subunits GcvH, and GcvH-L, primers were designed to amplify
each gene of interest (Table 2). lipM was amplified using primers 1494NC-F/1494N-R, lipA was
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amplified using primers 0829NC-F/0829-R, lipL was amplified using primers 0571NC-F/0571R, lplA1 was amplified using primers 0930NC-F/0930-R, lplA2 was amplified using primers
0328NC-F/0328-R, e2-PDH was amplified using primers 995hisNC-F/995his-R, e2-OGDH was
amplified using primers 1305hisNC-F/1305his-R, e2-BCODH was amplified using primers
1464hisNC-F/1464his-R, GcvH was amplified using primers 791hisNC-F/791his-R, and GcvH-L
was amplified using primers GcvH-LNC-F/GcvH-L-R. The resulting amplicon from each PCR
reaction was sub-cloned into pET-21a to generate a 6x-Histidine C-terminal tag and into pET15b to generate a 6x-Histidine N-terminal tag using NdeI and BamHI restriction endonucleases.
Plasmids containing genes of the lipoic acid biosynthesis and salvage pathway were transformed
into LysY IQ E. coli and plasmids containing the genes of the E2-subunits were transformed into
ΔlipA::kan LysY IQ E. coli to ensure each subunit was non-lipoylated. Both pET-21a and pET15b encode a lac operator upstream of the inserted gene that is induced by Isopropyl b-D-1thiogalactopyranoside (IPTG). After generation of plasmids capable of expressing 6x-His-LipM,
6x-His-LipA, 6x-His-LipL, 6x-His-LplA1, 6x-His-LplA2, 6x-His-PDH, 6x-His-OGDH, 6x-HisBCODH, 6x-His-GcvH, and 6x-His-GcvH-L, induction of protein expression was assessed by
growing the strains in LB for 3 hours at 37°C and then adding 1 mM IPTG to the culture for an
additional 3 hours to induce protein expression. Bacterial cell lysates were resolved on 12%
sodium dodecyl sulfate polyacrylamide gels at 120 V for 3 hours and total protein was visualized
via Coomassie staining using Gel Code Blue (Thermo Scientific). Strains that did not show
obvious induction of the protein of interest on a Coomassie stained gel were re-run on an SDSPAGE gel and transferred onto a 0.2 µM PVDF membrane at 1000 mA for 1 hour. The
membrane was incubated overnight in phosphate buffered saline + 0.1% Tween (PBST)
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containing 5% Bovine serum albumin (BSA) at 4°C. The membrane was then probed with a
1:3000 dilution of mouse anti-6x-Histidine antibody in PBST+ 5% BSA for 1 hour at room
temperature with rocking followed by three 15 min washes in PBST. Goat anti-mouse IgG HRP
conjugate was then added to the membrane at a 1:400 dilution for 1 hour followed by an
additional three 15 min washes in PBST. 6x-His tagged protein was visualized on an autoprocessor after addition of SuperSignal West Pico Chemiluminescent Substrate to the membrane
(Thermo).
Protein Purification of Lipoic Acid Biosynthesis and Salvage Enzymes
Enzymes of the lipoic acid biosynthesis and salvage pathway were purified using Ni2+
affinity chromatography. LysY IQ E. coli strains containing 6x-Histidine protein expression
plasmids for each of the lipoic acid biosynthesis and salvage enzymes were grown in 5 ml LB
with 100 µg/ml ampicillin at 37°C with shaking at 220 rpm overnight. The following day, the
bacteria were subcultured 1:100 and allowed to grow for 3 hours at 37°C until reaching an OD
600 of 0.25-0.3. Expression of the 6x-Histidine tagged proteins was induced with 0.1 mM IPTG
followed by incubation overnight at 16°C with shaking at 220 rpm. The next day, cultures were
spun down at 8500 rpm for 10 min at 4°C to collect the cell pellet followed by storage at -80°C.
In order to purify the recombinant proteins, bacterial pellets were thawed at 37°C and
resuspended in lysis buffer (25 mM imidazole, 50 mM Tris-HCL, 300 mM NaCl, pH 8)
supplemented with 1 mM dithiothreitol (DTT) and 1 mM phenylmethane sulfonyl fluoride
(PMSF). Using a Branson S-450A large tip sonicator, the bacteria were lysed at a constant rate of
0.8 seconds per pulse and an output of 340 W for 15 min on ice for 20 seconds at a time. The
lysed bacteria were then spun down for 30 min at 11,000 rpm followed by filtering the lysate
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using a 0.45 µm filter. The supernatant was then incubated with 1 ml nickel-NTA resin (Qiagen)
while rocking for 1 hour at 4°C. The resin was washed with 50 mM imidazole, 1 mM DTT, 50
mM Tris-HCL, 300 mM NaCl (pH 8) followed by elution of the bound protein using the same
buffer containing 500 mM Imidazole. In order to remove the imidazole, 10 kDa molecular
weight cut-off (MWCO) snakeskin dialysis tubing (Thermo Scientific) was used to dialyze the
purified protein into 100 mM imidazole + 50 mM Tris-HCL, 300 mM NaCl (pH 8) for 3 hours,
then 25 mM imidazole + 50 mM Tris-HCL, 300 mM NaCl (pH 8) overnight, and an additional 3
hours the following day in 50 mM Tris-HCL, 300 mM NaCl (pH 8). The concentration of the
purified protein was measured using a bicinchoninic acid (BCA) kit (Thermo Fisher) and stored
at -80°C. Protein purity was confirmed by loading 1 µg of purified protein on an SDS-PAGE gel
followed by Coomassie staining. Where necessary, proteins were further purified to homogeneity
using fast protein liquid chromatography (FPLC).
Protein Purification of the apo E2 and H Subunits of Lipoylated Enzyme Complexes
The E2-subunits of PDH, BCODH, OGDH, GcvH, and GcvH-L were purified from a
ΔlipA::kan LysY IQ E. coli strain using Ni2+ affinity chromatography. ΔlipA::kan LysY IQ E. coli
strains containing the 6x-Histidine expression plasmids for each of the apo E2 and H-subunits of
S. aureus lipoylated enzyme complexes were grown overnight in 30 ml LB with 100 µg/ml
ampicillin at 37°C with shaking at 220 rpm. The following day, the strains were subcultured
1:100 into LB with 100 µg/ml ampicillin and grown for 20 hours at 37°C with shaking at 220
rpm. The next day, cultures were induced with 0.5 mM IPTG for an additional 4 hours at 37°C
with shaking at 220 rpm. After induction, the bacterial cultures were spun down at 8500 rpm for
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10 min at 4°C and stored at -80°C overnight. The remaining steps of the purification of E2
subunits are the same as for the lipoic acid biosynthesis and salvage enzymes.
Lipoylation and Octanoylation Assays
Lipoylation assays were set up as described by Martin et al. (16). Assays were conducted
in 50 µl reaction volumes in a 50 mM Tris-HCl, 300 mM NaCl buffer (pH 8.0) containing 6 mM
ATP, 1 mM DTT, 1 mM MgCl2, 2 µM purified LplA1 or LplA2, and 10 µM substrate (apo E2PDH, apo E2-OGDH, apo E2-BCODH, apo GcvH, or apo GcvH-L). The reactions were
incubated with or without lipoic acid (2.4 mM), octanoic acid (2.4 mM), lipoamide (2.4 mM), or
DKLA (2.4 mM) for 2 hours at 37°C shaking at 600 rpm. After incubation, the reaction mixtures
were run out on 12% SDS-PAGE gels at 120 V for approximately 3 hours. SDS-PAGE gels were
stained with Gel Code Blue (Thermo Scientific) as a loading control and to visualize
octanoylation/lipoylation via a shift in band size. In addition, SDS-PAGE gels were transferred
to 0.2 µM PVDF membrane at 1000 mA for 1 hour. After transfer, the membrane was incubated
overnight in Tris-buffered saline + 0.1% Tween (TBST) containing 5% BSA at 4°C. The
following day, the membrane was probed with a 1:7500 dilution of rabbit anti-lipoic acid
antibody in TBST + 5% BSA for 1 hour at room temperature with rocking. Goat anti-rabbit IgG
AP conjugate was then added to the membrane at a 1:5000 dilution in TBST + 5% BSA for 1
hour at room temperature, followed by an additional three 15 min washes in TBST. Lipoylated
proteins were visualized using a colorimetric detection method by adding 66 µl of nitro-blue
tetrazolium (NBT) (50 mg NBT in 1 ml 70% dimethylformamide (DMF)/30% H2O) and 35 µl of
5-bromo-4-chloro-3’-indolyphosphate (BCIP) (50 mg BCIP in 1 ml DMF) to 10 ml AP Buffer
(100 mM Tris, 100 mM NaCL, 5 mM MgCl2, pH 9.5) and incubating the membrane with this
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solution for ~2 min rocking at room temperature. Development of the blot was stopped by
washing the membrane with water and allowing it to dry at 37°C for 15 min.

CHAPTER THREE
EXPERIMENTAL RESULTS
Introduction
Staphylococcus aureus is a Gram-positive commensal bacterium commonly found on the
skin, nasal passages, and in the gastrointestinal tract. In addition, S. aureus can also be a major
human pathogen in both hospital and community settings, where it is known to cause a wide
range of conditions such as mild skin and soft tissue infections (SSTI), bacteremia, sepsis, and
osteomyelitis (4; 9; 11). The success of S. aureus as a pathogen stems from its ability to infect a
wide range of host tissues. In order to thrive in such diverse environments, S. aureus uses
multiple adaptive traits such as trace metal/nutrient acquisition, shifts in metabolic activity, and
expression of detoxification systems, all of which allow the bacterium to proliferate and survive
in nutritionally deficient and inhospitable environments (8; 9; 11).
Instrumental to survival in nutrient restricted environments is the ability of S. aureus to
acquire trace metals and other metabolic cofactors important for optimal metabolism. One
essential metabolite used by S. aureus is lipoic acid. A former graduate student, Azul Zorzoli,
used a genetic approach to define the lipoic acid biosynthesis and salvage pathways of S. aureus.
Her studies determined that S. aureus synthesizes lipoic acid de novo from an octanoic acid
precursor, or through salvage mechanisms, where free lipoic acid is acquired from the
environment by the action of lipoic acid ligases, LplA1 and LplA2. In the Firmicutes phylum, S.
aureus is the only pathogenic bacterium that encodes all de novo biosynthesis genes, as well as
35
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two lipoic acid ligases involved in salvage (8). Azul’s data demonstrated that LplA1, but not
LplA2, is necessary for the salvage of lipoic acid in vitro, whereas both LplA1 and LplA2 are
sufficient to promote infection of specific tissues in vivo. Furthermore, the work of Rack et al.
suggests that lplA2 gene expression is sub-optimal in vitro (72). Because the LplA2 ligase does
not have a discernable function in vitro, its exact role in lipoic acid salvage is unknown. Based
on these two pieces of information, I hypothesized that LplA1 and LplA2 stimulate growth by
using alternative lipoylated substrates and/or that lplA2 gene expression is induced in vivo
compared to LplA1.
Construction of Lipoic Acid Ligase Mutants (DlipA DlplA1 and DlipM DlplA1) to Test the
Function of LplA2 In Vitro
Current literature states that L. monocytogenes encodes two lipoic acid ligases, LplA1
and LplA2, which have been shown to use alternative lipoylated substrates (54; 53). In addition,
our preliminary data suggest that LplA2 in S. aureus has a functional role in vivo, however its
activity could not be demonstrated in vitro. Based on this information, I hypothesized that LplA2
may use alternative lipoylated substrates in vivo to stimulate bacterial replication. I constructed
DlipA DlplA1 and DlipM DlplA1 in-frame deletion mutants in order to ascertain the potential
divergent activities of LplA2 and test its ability to use alternative sources of lipoic acid. DlipA
DlplA1 and DlipM DlplA1 in-frame deletion mutants were verified by PCR amplification using
primers that anneal 500 bp upstream and 500 bp downstream of genes lipA, lplA1, and lipM.
PCR amplification resulted in a ~2 kb amplicon for all WT alleles (lipA, lipM, and lipL are each
approximately 1 kb) and a ~1kb band for mutant DlipA, DlipM, and DlplA1 alleles (Fig 8A and
8B). These data indicate successful construction of DlipA DlplA1 and DlipM DlplA1 mutants.
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These mutants will be used in conjunction with already constructed DlipA, DlipA DlplA2, DlipA
DlplA1 DlplA2, DlipA DlplA1 DlplA2 + lplA1, DlipA DlplA1 DlplA2 + lplA2, and DlipA DlplA1
DlplA2 DlipL::kan mutants, to assess the ability of both LplA1 and LplA2 to use a variety of
lipoylated substrates in vitro.

Figure 8. Verification of DlipADlplA1 and DlipMDlplA1 mutants via PCR
PCR samples were run out on a 0.8% agarose gel to A. verify the deletion of DlipA and DlipM and B. Verify the
deletion of DlplA.

Identify the Substrates Used by LplA1 and LplA2 by Assessing Growth Phenotypes after
Supplementation with Different Lipoylated Substrates
Our preliminary data suggest that LplA1 uses free lipoic acid during in vitro growth
whereas LplA2 does not. Nevertheless, it remains to be determined if either of the ligases can use
alternative lipoylated substrates as a source of lipoic acid (71). As mentioned previously, L.
monocytogenes encodes two lipoic acid ligases, LplA1 and LplA2, one of which uses alternative
lipoylated substrates for growth (54; 53). From these data, I hypothesized that LplA2 uses
lipoylated substrates other than free lipoic acid to stimulate growth in vitro. In order to assess the
ability of LplA2 to use alternative lipoylated substrates, I conducted growth curves supplemented
with lipoic acid, lipoamide, digested/undigested OGDH, digested/undigested PDH, and octanoic
acid using WT, DlipA, DlipA DlplA1, DlipA DlplA2, DlipA DlplA1 DlplA2, DlipA DlplA1 DlplA2 +

lplA1, DlipA DlplA1 DlplA2 + lplA2, and DlipA DlplA1 DlplA2 DlipL strains. When the medium
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was supplemented with lipoic acid and lipoamide, DlipA, DlipA DlplA2 and DlipA DlplA1 DlplA2
+ lplA1 mutants replicated, whereas DlipA DlplA1 and DlipA DlplA1 DlplA2 + lplA2 mutants
were not able to grow (Fig 9A and 9B). As suspected, when the medium was supplemented with
undigested PDH and OGDH only the WT strain replicated (Fig 10A and 10B). Contrary to my
initial hypothesis, neither digested OGDH nor digested PDH could stimulate growth of the DlipA
DlplA1 and DlipA DlplA1 DlplA2 + lplA2 strains (Fig 11A and 11B). Instead, DlipA, DlipA DlplA2
and DlipA DlplA1 DlplA2 + lplA1 mutants were able to replicate using digested PDH but not
digested OGDH (Fig 11A and 11B). When the growth medium was supplemented with octanoic
acid, the mutant strains were not able to grow due to a non-functional de novo biosynthesis
pathway, similar to RPMI medium without supplements (Fig 12A and 12B). These data indicate
that LplA1 may have substrate specificities that extend beyond free lipoic acid and that LplA2
appears to play no apparent role in using lipoic acid or alternative substrates of lipoic acid in
vitro.
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Figure 9. LplA1, but not LplA2, uses free lipoic acid and lipoamide as a lipoyl substrate
Growth assessment of lipoic acid ligase mutants in RPMI supplemented with A. Lipoic acid (10 µg/ml) and B.
Lipoamide (10 µg/ml). Strains colored in orange test for the function of LplA1, whereas the strains colored in green
test for the function of LplA2.
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Figure 10. Neither LplA1 nor LplA2 use undigested OGDH and PDH to stimulate growth
Growth assessment of lipoic acid ligase mutants in RPMI supplemented with A. undigested OGDH (1.16 mg/ml)
and B. undigested PDH (2.5 mg/ml). Strains colored in orange test for the function of LplA1, whereas the strains
colored in green test for the function of LplA2.
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Figure 11. Only LplA1 uses digested PDH, but not digested OGDH, to stimulate growth
Growth assessment of lipoic acid ligase mutants in RPMI supplemented with A. digested OGDH (1.15 mg/ml) and
B. digested PDH (2.5 mg/ml). Strains colored in orange test for the function of LplA1, whereas the strains colored in
green test for the function of LplA2.
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Figure 12. S. aureus lipoic acid biosynthesis and salvage mutants cannot grow in lipoic acid free medium
Growth assessment of lipoic acid ligase mutants in RPMI supplemented with A. octanoic acid (6.9 µg/ml) and B.
RPMI alone. Strains colored in orange test for the function of LplA1, whereas the strains colored in green test for
the function of LplA2.
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Assessing the Ability of LplA1 and LplA2 to Use Synthetic Lipoylated (DK A) and NonL

Lipoylated (DKA) Tripeptides
As mentioned previously, I know that lipoic acid ligases from at least one other
bacterium have affinity for different lipoylated substrates and my data suggest that LplA1 can
use lipoylated PDH peptides to stimulate growth (54; 53). A potential pitfall of these lipoylsubstrate addition studies is that they used entire PDH and OGDH complexes as sources of lipoic
acid, even though it is known that only the E2 subunits contain lipoyl moieties. When porcine
PDH and OGDH are digested with proteinase K the smallest lipoyl peptide achieved is DKLA
and DKLT respectively (54). In addition, the PDH and OGDH tripeptide sequences share
similarity with human, murine, and rat lipoyl domains (Fig 13A and 13B). Therefore, I repeated
the growth curves using synthetic lipoylated and non-lipoylated DKA to ensure that other
components of the PDH complex do not facilitate growth by a mechanism that does not depend
on lipoic acid. Based on this information and previous observations, which indicated the ability
of LplA1 to use PDH as a source of lipoic acid, I hypothesized that LplA1, but not LplA2 would
stimulate bacterial growth when supplemented with DKLA. In order to assess the ability of
LplA1 and LplA2 to use the tripeptide DKLA and DKA, I conducted growth curves using WT,
DlipA, DlipA DlplA1, DlipA DlplA2, DlipA DlplA1 DlplA2, DlipA DlplA1 DlplA2 + lplA1, DlipA
DlplA1 DlplA2 + lplA2, and DlipA DlplA1 DlplA2 DlipL strains. When the growth medium was
supplemented with DKLA, both DlipA DlplA2 and DlipA DlplA1 DlplA2 + lplA1 were able to
grow, whereas DlipA DlplA1 and DlipA DlplA1 DlplA2 + lplA1 strains were not (Fig 14A). As
expected, when RPMI medium was supplemented with DKA only the WT strain was able to
replicate (Fig 14B). These data are consistent with my previous growth curves using digested

44
PDH complexes and suggest that only LplA1 is able to use peptide bound lipoic acid, or that
LplA2 is not sufficiently expressed under these conditions.
B.

A.
E2- PDH
Homo sapien
Sus scrofa
Rattus norvegicus
Mus musculus

E2- OGDH
L

VETDK ATVG
IETDKLATIG
VETDKLATVG
IETDKLATIG
VETDKLATVG
IETDKLATIG
VETDKLATVG
IETDKLATIG

Homo sapien

IETDKLTSVQ

Sus scrofa

IETDKLTSVQ

Rattus norvegicus IETDKLTSVQ
Mus musculus

IETDKLTSVQ

Figure 13. Amino acid sequences of the lipoyl domains from PDH and OGDH complexes
A. PDH lipoyl domain from Homo sapien (NP_001922.2 ), Sus scrofa (NP_999159.1), Rattus norvegicus
(NP_112287.1 ), and Mus musculus (NP_663589.3 ) B. OGDH lipoyl domain from Homo sapien (NP_001231812.1
), Sus scrofa (NP_999159.1 ), Rattus norvegicus (NP_001006982.2 ), and Mus musculus (NP_084501.1 )
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Figure 14. Only LplA1 uses DKLA as a source of lipoyl substrate
Growth assessment of lipoic acid ligase mutants in RPMI supplemented with A. DKLA (100 µM) and B. DKA (100
µM). Strains colored in orange test for the function of LplA1, whereas the strains colored in green test for the
function of LplA2.
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Assessing the Ability of LplA1 and LplA2 to use Synthetic Lipoylated (DK T) and NonL

Lipoylated (DKT) Tripeptides
The above studies indicated that only LplA1 can use digested PDH, but not digested
OGDH as a source of lipoic acid. To ensure that other components of digested PDH did not
stimulate growth, I repeated the growth curves with the smallest known lipoyl moiety, DKLA,
when PDH is digested with proteinase K. Consistent with my previous data from growth curves
supplemented with digested PDH, only LplA1 was able to use DKLA to stimulate bacterial
replication. When OGDH is digested with proteinase K, the smallest known lipoyl moiety
achieved is a DKLT tripeptide. Since digested OGDH and digested PDH have different amino
acids flanking the lipoylated lysine and only digested PDH stimulated bacterial growth, I
hypothesized that LplA1 can only recognize the lipoyl moiety in a specific context of these
amino acids and will not be able to use DKLT to stimulate bacterial growth. To test this
hypothesis and assess the ability of LplA1 and LplA2 to use the synthetic lipoylated and nonlipoylated DKT tripeptide, I conducted growth curves using WT, DlipA, DlipA DlplA1, DlipA
DlplA2, DlipA DlplA1 DlplA2, DlipA DlplA1 DlplA2 + lplA1, DlipA DlplA1 DlplA2 + lplA2, and
DlipA DlplA1 DlplA2 DlipL strains. Contrary to my proposed hypothesis but consistent with my
previous data, both DlipA DlplA2 and DlipA DlplA1 DlplA2 + lplA1 were able to grow, whereas
DlipA DlplA1 and DlipA DlplA1 DlplA2 + lplA1 strains were not when RPMI medium was
supplemented with DKLT and DKLA (Fig 15A and 15B). As expected, when I supplemented the
RPMI medium with the non-lipoylated DKT and DKA tripeptide, only the WT strain was able to
grow (Fig 15C and 15D). These data suggest that only LplA1, and not LplA2, can recognize the
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lipoyl moiety on the conserved lysine in the context of different amino acids and that other
components of digested OGDH may inhibit LplA1 to efficiently use the OGDH lipoyl moiety.
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Figure 15. Both DKLA and DKLT stimulate bacterial replication in the presence of LplA1 but not LplA2
Growth assessment of lipoic acid ligase mutants in RPMI supplemented with A. DKLT (100µM), B. DKLA
(100µM), C. DKT (100µM) and D. DKA (100µM). Strains colored in orange test for the function of LplA1,
whereas the strains colored in green test for the function of LplA2.

Generation of a Transcriptional Reporter Fusion of the PlplA2 Promoter to gfp
In a recent study, Rack et al. suggested that LplA2 in S. aureus is responsible for
lipoylating the GcvH-like protein, GcvH-L, using lipoic acid or lipoamide. This lipoylation
allows for subsequent ADP-ribosylation of GcvH-L by a macrodomain-linked sirtuin (SirTM).
These post-translational modifications were hypothesized to promote resistance to host oxidative
stress responses and thereby permit bacterial survival during infection, however this activity has
yet to be verified (72; 73). Interestingly, this study, as well as early transcriptome work, alludes
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to the fact that the lack of LplA2 activity in vitro may be due to low levels of gene expression in
the in vitro growth conditions used (73). Based on this information and my prior data which was
unable to demonstrate LplA2 activity in vitro, I hypothesized that the induction of redox stress
conditions may allow for increased lplA2 gene expression and better incorporation of lipoic acid.
In order to further elucidate the regulatory inputs that facilitate lplA2 gene expression, I
generated a transcriptional reporter by fusing the predicted promoter region of lplA2 to gfp. With
this promoter fusion, I will be able to use gfp expression to directly measure lplA2 promoter
activity under a variety of environmental conditions. Since the promoter region of lplA2 is
unknown and a small putative gene exists 100 bp upstream of the first gene in the lplA2 operon
(LLM), I generated a short (100 bp) and long (300 bp) pOS1-PlplA2-gfp construct and transformed
both into DlipA DlplA1 and DlipM DlplA1 strains in order to assess lplA2 gene expression (Fig
16). To verify the presence of the desired promoter element in these plasmids, I PCR amplified
both the 100 bp and 300 bp target regions and ran them on a 1.2% agarose gel. The outcome of
these PCRs determined that the DlipA DlplA1 and DlipM DlplA1 strains each harbored the
appropriate gfp reporter plasmid corresponding to the short (~100bp) and long (~300bp) putative
lplA2 promoter region when compared to the WT genomic DNA control (Fig 16). These data
indicate that I have successfully transformed the short and long pOS1-PlplA2-gfp promoter fusions
into DlipA DlplA1 and DlipM DlplA1 strains. Due to time constraints and per recommendation by
my committee, I decided to focus my attention on assessing the functional differences between
LplA1 and LplA2 using biochemical approaches instead of lplA2 expression under different
stress conditions.

A.

B.
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Figure 16. Verification of short and long pOS1-PlplA2-gfp promoter fusions in DlipA DlplA1 and DlipM
DlplA1 mutants via PCR
PCR samples were resolved on a 0.8% agarose gel to A. Verify the introduction of the short pOS1-PlplA2-gfp plasmid
into DlipA DlplA1 and DlipM DlplA1 strains and B. Verify the introduction of the long pOS1-PlplA2-gfp into DlipA
DlplA1 and DlipM DlplA1 strains.

Generation of 6x-Histidine Tagged Protein Expression Constructs of the Five Lipoic Acid
Biosynthesis and Salvage Enzymes
In our previous studies, a genetic approach was used to identify the genes involved in
lipoic acid biosynthesis and salvage in S. aureus (71). However, the precise activity of LplA1
and LplA2 and their substrate usage remains to be determined. I hypothesized that LplA1 and
LplA2 are responsible for facilitating lipoylation of the metabolic complexes PDH, OGDH,
BCODH, GcvH, and GcvH-L, although the two enzymes may have differing affinities and/or
activities. In order to assess the functions of LplA1 and LplA2 biochemically, I first needed to
express and purify recombinant LplA1 and LplA2 and their potential substrates/interacting
partners. In order to purify the recombinant proteins, I generated 6x-Histidine tagged protein
expression plasmids and screened for induction of LipM, LipA, LipL, LplA1, and LplA2 in the
presence of 1mM IPTG. When IPTG was added to the culture medium to induce gene
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expression, I observed overexpression of LipM, LipA, and LipL when whole cell lysates were
resolved on an SDS-PAGE gel stained with Coomassie dye compared to uninduced controls (Fig
17). However, no apparent overexpression was seen for LplA1 and LplA2 (Fig 18), indicating
that either they do not express the 6x-Histidine tagged protein or that expression is not high
enough to detect on a Coomassie stained gel. In order to assess whether these 6x-Histidine
tagged constructs are expressing LplA1 and LplA2, I performed immunoblots using an anti-6xHistidine antibody to visualize the tagged proteins (Fig 18). These immunoblots indicated that
LplA1 and LplA2 were being induced, albeit at lower levels than LipA, LipM, and LipL.
Together these data indicate that N-terminal 6x-Histidine tagged LipM, LipA, LipL, LplA1, and
LplA2 can successfully be overexpressed in E. coli.

Figure 17. 6x-Hisitidine tagged LipM, LipA, and LipL of the de novo biosynthesis pathway can be
successfully overexpressed with the addition of 1mM IPTG

Bacterial whole cell lysates of LysY IQ E. coli strains harboring 6x-His-LipM, 6x-His-LipA, or 6x-His-LipL,
induced with or without 1 mM IPTG, were resolved on an SDS PAGE gel and stained with Coomassie blue to assess
the ability for each strain to overexpress the 6x-Histidine tagged protein.
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Figure 18. Trial Induction and Immunoblot of 6x-Hisitdine tagged LplA1 and LplA2

Bacterial whole cell lysates of LysY IQ E. coli strains harboring 6x-His-LplA1 or 6x-His-LplA2, induced with 1mM
IPTG, were resolved on an SDS PAGE gel and stained with Coomassie blue or transferred and used in immunoblots
probed with mouse anti-6x-Histidine antibody.

Purification of 6x-Histidine Tagged Lipoic Acid Biosynthesis and Salvage Enzymes from E.
coli and Apo E2-PDH, Apo E2-OGDH, Apo E2-BCODH, Apo GcvH, and Apo GcvH-L
from DlipA E. coli
In order to evaluate the role of LplA1 and LplA2 in the lipoic acid salvage pathway and
further investigate the sequential steps of lipoylation, I purified the five 6x-Histidine tagged
proteins of the de novo biosynthesis and salvage pathway and the corresponding substrates E2PDH, E2-OGDH, E2-BCODH, GcvH, and GcvH-L. To verify purity of the proteins, I ran an
SDS PAGE gel of the five enzymes of the de novo biosynthesis and salvage pathway and the
purified apo E2-subuntis of PDH, OGDH, BCODH, GcvH, and GcvH-L (~1 µg loaded) (Fig
19A and 19B). I expected to see a 36 kDa band for LplA1, a 37 kDa band for LplA2, a 30 kDa
band for LipM, a 28 kDa band for LipL, and a 33 kDa band for LipA. In addition, I expected to
see a 72 kDa band for PDH, a 65 kDa band for OGDH, a 51 kDa band for BCODH, a 23 kDA
band for GcvH, and a 20 kDa band for GcvH-L. All purified proteins had the correct anticipated
size (Fig 19). These data indicate that I have successfully purified all of the lipoic acid
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biosynthesis and salvage enzymes, as well as apo E2-PDH, apo E2-OGDH, apo E2-BCODH,
apo GcvH, and apo GcvH-L proteins.

A.

B.

Figure 19. Purified proteins of the de novo biosynthesis and salvage pathway and purified lipoyl domains
of the known lipoylated enzyme complexes
A. Coomassie blue staining of purified LplA1, LplA2, LipM, LipL, and LipA on a 12% SDS PAGE gel, ~1µg
loaded B. Coomassie blue staining of purified apo E2-PDH, apo E2-OGDH, apo E2-BCODH, apo GcvH, and apo
GcvH-L on a 12 % SDS PAGE gel, ~1µg loaded.

Assessing the Activity and Substrate Usage of LplA1 and LplA2 In Vitro
Only LplA1 Lipoylates Apo GcvH.
Our previous genetic evidence suggests that LplA1 is able to lipoylate GcvH using lipoic
acid in vitro, however no such activity has been detected for LplA2 (71). Therefore, I tested
whether or not LplA2 is capable of directly lipoylating H subunits by conducting lipoylation
assays with GcvH in the presence of lipoic acid, lipoamide, the tripeptide DKLA, and octanoic
acid followed by resolving lipoylation reactions on an SDS-PAGE gel and staining with
Coomassie dye or transferring to PVDF membranes and immunoblotting with anti-lipoic acid
antibody. When the reaction was supplemented with free lipoic acid, I detected a lipoyl band and
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shift in band size on the Coomassie-stained gel for the reaction containing LplA1, but not for
LplA2 (Fig 20A). When incubated with lipoamide, I detected a lipoyl band but no shift in band
size on the Coomassie-stained gel for LplA1, whereas no lipoylation was detected with LplA2
(Fig 20B). The lipoyl band detected upon incubation with LplA1 was more intense when the
reaction was incubated with lipoic acid rather than lipoamide. I did not detect a lipoyl band for
either LplA1 or LplA2 when the reaction was incubated with DKLA (Fig 20C). When I assessed
the ability of LplA1 and LplA2 to octanoylate GcvH, I also detected a shift in band size on the
Coomassie-stained gel for LplA1, but not LplA2 (Fig 20D). Currently the lab does not have an
anti-octanoic acid antibody that is functional in immunoblotting procedures; as a result
octanoylation was only evaluated via a shift in band size. Overall, these data indicate that LplA1,
but not LplA2, directly lipoylates/octanoylates apo-GcvH using lipoic acid, lipoamide, and
octanoic acid. However, due to the increased intensity of the lipoyl band and shift in band size in
the presence of lipoic acid, it appears that lipoic acid is the preferred substrate used by LplA1 to
lipoylate apo GcvH.
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Figure 20. LplA1, but not LplA2, directly uses lipoic acid, lipoamide, and octanoic acid to
lipoylate/octanoylate apo GcvH
Biochemical assessment of LplA1 and LplA2 lipoylation/octanoylation of apo GcvH using A. lipoic acid (2.4 µM)
B. lipoamide (2.4 µM) C. DKLA (2.4 µM) and D. octanoic acid (2.4 µM). Lipoylation was visualized by resolving
reactions on a 12% SDS PAGE gel stained with Coomassie blue (top panel) and conducting an immunoblot (bottom
panel) probed with a mouse anti-lipoic acid antibody (anti-LA). Octanoylation was visualized on a 12% SDS PAGE
gel stained with Coomassie blue (top panel).

Both LplA1 and LplA2 Lipoylate Apo GcvH-L.
Based on the genome database, it is known that S. aureus encodes two GcvH proteins,
GcvH and GcvH-L, and two lipoic acid ligases. In addition, it is known that both LplA2 and
GcvH-L are encoded in the same operon. Since my data indicate that only LplA1 is responsible
for lipoylating GcvH, I reasoned that LplA2 is responsible for lipoylating GcvH-L. To test this
assertion, I determined whether LplA1 and LplA2 are able to lipoylate GcvH-L using lipoic acid,
lipoamide, the tripeptide DKLA, or octanoic acid. When the reaction was incubated with free
lipoic acid, I detected lipoyl bands and observed a shift in GcvH-L band size on the Coomassie
stained gel for reactions containing either LplA1 or LplA2 (Fig 21A). The lipoyl band from the
reaction containing LplA1 appeared more intense compared to LplA2 (Fig 21A). In addition, I
detected lipoyl bands for both LplA1 and LplA2 when the reaction was supplemented with
lipoamide (Fig 21B). I did not detect lipoyl bands for either LplA1 or LplA2 when the reaction
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was supplemented with DK A (Fig 21C). Lastly, when incubated with octanoic acid, I observed
L

a shift in GcvH-L band size on the Coomassie stained gel for the reactions containing both
LplA1 and LplA2 compared to the negative control (Fig 21D). These data indicate that both
LplA1 and LplA2 can use lipoic acid and lipoamide to lipoylate apo GcvH-L and octanoic acid
as a source for octanoylation of apo GcvH-L.

Figure 21. Both LplA1 and LplA2 directly lipoylate and octanoylate apo GcvH-L using lipoic acid,
lipoamide and octanoic acid
Biochemical assessment of LplA1 and LplA2 lipoylation/octanoylation of apo GcvH-L using A. lipoic acid (2.4
µM) B. lipoamide (2.4 µM) C. DKLA (2.4 µM) and D. octanoic acid (2.4 µM). Lipoylation was visualized by
resolving reactions on a 12% SDS PAGE gel stained with Coomassie blue (top panel) and conducting an
immunoblot (bottom panel) probed with a mouse anti-lipoic acid antibody (anti-LA). Octanoylation was visualized
on a 12% SDS PAGE gel stained with Coomassie blue (top panel).

Both LplA1 and LplA2 Lipoylate Apo E2-OGDH.
Prior genetic evidence suggested that LipL is primarily responsible for lipoylating apo
E2-OGDH, however, when a DlipL mutant was grown in RPMI+BCFA, low levels of lipoylation
on OGDH was seen (71). It was determined that these low levels of lipoylation were due to
LplA1. To determine if LplA1 lipoylates E2-OGDH, I conducted lipoylation assays using apo
E2-OGDH in the presence of lipoic acid, lipoamide, DKLA, and octanoic acid. In the presence of
free lipoic acid, I detected a lipoyl band for the reactions containing both LplA1 and LplA2 (Fig

56
22A). The intensity of the lipoyl band from the reaction containing LplA2 appeared more
pronounced than the reaction containing LplA1 (Fig 22A). When the reaction was repeated using
lipoamide as a substrate, I only detected a lipoyl band for the reaction containing LplA1 (Fig
22B). No lipoyl bands were detected for reactions containing LplA1 or LplA2 in the presence of
DKLA (Fig 22C). In addition, although I tested the ability of LplA1 and LplA2 to octanoylate
apo E2-OGDH, my results were inconclusive because I do not have a positive control to verify
that octanoylation occurred (Fig 22D). Together, these data indicate that both LplA1 and LplA2
directly lipoylate apo E2-OGDH using lipoic acid as a substrate, and LplA2 does so with
apparent increased efficiency. In contrast, only LplA1 directly lipoylates apo E2-OGDH using
lipoamide as a substrate.

Figure 22. Both LplA1 and LplA2 lipoylate apo E2-OGDH using lipoic acid, however only LplA1
lipoylates apo E2-OGDH using lipoamide
Biochemical assessment of LplA1 and LplA2 lipoylation/octanoylation of apo E2-OGDH using A. lipoic acid (2.4
µM) B. lipoamide (2.4 µM) C. DKLA (2.4 µM) and D. octanoic acid (2.4 µM). Lipoylation was visualized by
resolving reactions on a 12% SDS PAGE gel stained with Coomassie blue (top panel) and conducting an
immunoblot (bottom panel) probed with a mouse anti-lipoic acid antibody (anti-LA). Octanoylation was visualized
on a 12% SDS PAGE gel stained with coomassie blue (top panel).
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Only LplA2 Lipoylates Apo E2-PDH.
Based on my observation of different lipoylation activities for LplA1 and LplA2 with
GcvH, GcvH-L and E2-OGDH, I reasoned that E2-PDH might also exhibit unique lipoylation
characteristics that depend on lipoyl sources or ligases. To test the ability of LplA1 and LplA2 to
lipoylate apo E2-PDH I conducted lipoylation assays in the presence of lipoic acid, lipoamide,
and the tripeptide DKLA followed by resolving lipoylation reactions on an SDS-PAGE gel and
staining with Coomassie dye or transferring to PVDF membranes and immunoblotting with antilipoic acid antibody. When incubated with free lipoic acid, I detected a lipoyl band for the
reaction containing LplA2, but not LplA1 (Fig 23A). In contrast, no lipoyl protein bands were
detected for reactions containing LplA1 or LplA2 in the presence of lipoamide or DKLA (Fig
23B and 23C). These data indicate that LplA2, but not LplA1 is able to lipoylate apo E2-PDH
directly using lipoic acid as a substrate. Neither LplA1 nor LplA2 are able to incorporate lipoic
acid using lipoamide or DKLA as a substrate.

Figure 23. Only LplA2 directly lipoylates PDH using lipoic acid
Biochemical assessment of LplA1 and LplA2 lipoylation of apo E2-PDH using A. lipoic acid (2.4 µM) B. lipoamide
(2.4 µM) C. DKLA (2.4 µM) and D. octanoic acid (2.4 µM). Lipoylation was visualized by resolving reactions on a
12% SDS PAGE gel stained with Coomassie blue (top panel) and conducting an immunoblot (bottom panel) probed
with a mouse anti-lipoic acid antibody (anti-LA).
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Only LplA2 Lipoylates Apo E2-BCODH.
Lastly, in order to test the ability of LplA1 and LplA2 to lipoylate apo E2-BCODH, I
conducted the same lipoylation assays using lipoic acid, lipoamide, the tripeptide DKLA, and
octanoic acid as a substrate. In the presence of lipoic acid, I detected a lipoyl band for the
reaction containing LplA2 (Fig 24A). However, no lipoyl bands were detected for reactions
containing LplA1 or LplA2 in the presence of lipoamide and DKLA (Fig 24B-C). Reactions were
repeated using octanoic acid as a substrate, however without a positive control I could not
determine whether or not octanoylation of apo E2-BCODH occurred (Fig 24D). Consistent with
my results for apo E2-PDH, these data suggest that LplA2 can directly lipoylate apo E2-BCODH
using lipoic acid as a substrate whereas, neither LplA1 nor LplA2 can lipoylate apo E2-BCODH
using lipoamide or DKLA as a source of lipoic acid.

Figure 24. Only LplA2 lipoylates apo E2-BCODH using lipoic acid
Biochemical assessment of LplA1 and LplA2 lipoylation/octanoylation of apo E2-BCODH using A. lipoic acid (2.4
µM) B. lipoamide (2.4 µM) C. DKLA (2.4 µM) and D. octanoic acid (2.4 µM). Lipoylation was visualized by
resolving reactions on a 12% SDS PAGE gel stained with Coomassie blue (top panel) and conducting an
immunoblot (bottom panel) probed with a mouse anti-lipoic acid antibody (anti-LA). Octanoylation was visualized
on a 12% SDS PAGE gel stained with Coomassie blue (top panel).
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Taken together, these data suggest that LplA1 appears to possess a more limited range of
lipoylation targets that includes both H subunits (GcvH and GcvH-L) and one E2 subunit (E2OGDH). In contrast LplA2 appears to have a broader capacity to target and lipoylate targets
including all E2 subunits (E2-PDH, E2-OGDH, and E2-BCODH) as well as the secondary H
subunit GcvH-L. Furthermore, each enzyme predominantly uses free lipoic acid as a substrate
with limited ability to incorporate lipoamide and octanoic acid onto select targets. These data
demonstrate that each ligase has its own preferred source of substrate and targets for lipoylation
and that they can act independently from one another.

CHAPTER FOUR
DISCUSSION
Introduction
Pathogens such as S. aureus have developed pathways important for the acquisition of
metabolites and nutrients. It has been shown that a number of these pathways are crucial for
bacterial survival during host infection (15; 74). One such pathway is the lipoic acid biosynthesis
and salvage pathway of S. aureus, which is responsible for the synthesis and scavenging of the
vital cofactor lipoic acid. Unlike other pathogenic Firmicutes, the salvage pathway of S. aureus
is unique as it is composed of two lipoic acid ligases, LplA1 and LplA2, important for
scavenging lipoic acid from the environment (71). Prior work in the Alonzo lab determined that
only LplA1 scavenges lipoic acid in vitro, whereas both ligases are crucial for host infection in
vivo, leaving the exact role of LplA2 undetermined (71). My aim in this thesis was to further
explore the functions of the lipoic acid ligases in S. aureus and assess their ability to use lipoic
acid as well as alternative sources of lipoic acid. My data suggest that only LplA1, and not
LplA2, can scavenge lipoic acid and peptide bound lipoyl domains from different sources under
conditions used in this thesis, even when LplA2 is expressed from a constitutive promoter.
However, my biochemical data indicate that both LplA1 and LplA2 are functional and can
directly lipoylate S. aureus lipoyl enzyme complexes. In addition, my data suggest that both
ligases in S. aureus have preferred targets for lipoylation and can act independently from one
another. Overall, these data highlight the importance of the divergent functions of LplA1 and
60
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LplA2 and may explain why S. aureus thrives so well when faced with low levels of free lipoic
acid during host infection.
LplA1, but not LplA2, Can Use Free Lipoic Acid and Lipoylated Peptides to Stimulate
Growth In Vitro
To test the possible divergent functions of LplA1 and LplA2, I first assessed the ability of
either DlipA DlplA1 and DlipA DlplA2 mutants to use free lipoic acid and other lipoyl sources
from proteins and small peptides. Prior data have shown that LplA2 is functional and stimulates
bacterial growth when RPMI medium is supplemented with 20% FBS (71). However, addition of
free lipoic acid to this medium does not increase bacterial growth, suggesting that LplA2dependent growth requires FBS and is not enhanced by free lipoic acid (71). These data initially
led me to hypothesize that LplA2 stimulates bacterial growth by facilitating the use of alternative
sources of lipoic acid – perhaps lipoyl peptides in the serum. However, in the absence of LplA1,
a DlipA DlplA1 mutant and DlipA DlplA1 DlplA2 + lplA2 strain, where lplA2 is expressed under a
constitutive promoter, were not able to grow in the presence of lipoic acid, lipoamide, octanoic
acid, digested and undigested PDH, or digested and undigested OGDH. Contrary to my proposed
hypothesis, these data suggest that LplA2 cannot recognize lipoic acid in the context of a
peptide, even when it is being overexpressed. This is unusual considering our determination that
FBS stimulates growth in an LplA2-dependent manner, which we presumed to be due to the use
of lipoyl peptides or other derivatives. Interestingly, a DlipA DlplA1 DlplA2 + lplA2 strain, with
constitutively expressed LplA2, does not grow when RPMI medium is supplemented with 20%
FBS. It may be possible that lplA2 is not being translated in a DlipA DlplA1 DlplA2 + lplA2 strain
grown under these conditions. One way to address this issue would be to a run the bacterial

lysate of the DlipA DlplA1 DlplA2 + lplA2 strain on an SDS PAGE gel and conduct an
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immunoblot probed with an anti-LplA2 antibody to assess whether this strain produces LplA2. In
addition, these data also suggest that additional factors not found under these conditions may be
important for the LplA2 ligase to be functional.
From the genome sequence, I know that lplA2 is encoded in an operon with four
additional genes (LLM, gcvH-L, macro, and sirTM) (Fig 25). It is conceivable that expression of
these genes is important for the function of LplA2 in vitro. In addition, research has shown that
LplA2 is responsible for lipoylating GcvH-L under oxidative stress conditions in both S. aureus
and Streptococcus pyogenes (72). Based on this information and the fact that I was not able to
detect growth for the DlipA DlplA1 DlplA2 + lplA2 mutant in vitro but saw growth in vivo, I
speculate that other components in vivo, such as oxidative stress, may be crucial for the
expression of the additional genes in the LplA2 operon and required for LplA2 to function and
stimulate bacterial growth. Evidence for this comes from Zorzoli et al., where mice were
infected with WT, DlipA DlplA1 DlplA2, DlipA DlplA1 DlplA2 + lplA1, and DlipA DlplA1 DlplA2
+ lplA2 to determine if the ligases had overlapping functions in vivo (71). As expected, the triple
mutant was nearly avirulent in mice since it does not have a functional lipoic acid de novo
biosynthesis or salvage pathway, however both complement strains, DlipA DlplA1 DlplA2 +
lplA1 and DlipA DlplA1 DlplA2 + lplA2, had similar bacterial burden compared to the WT
implying that LplA2 is expressed and functional under these conditions (71). This was a very
interesting finding since it supports the idea that additional factors found in vivo may be
responsible for LplA2 functionality. It is tempting to speculate that the host environment leads to
the upregulation of the lplA2 operon to promote activity of LplA2. To further explore this notion,
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I would repeat the growth curves described in this thesis under oxidative stress conditions to
assess whether or not the DlipA DlplA1 DlplA2 + lplA2 strain is able to grow. In addition, I would
repeat in vivo experiments with strains containing deletions of the other genes in the lplA2
operon (LLM, gcvH-L, macro, and sirTM) to assess whether or not these genes are responsible
for promoting LplA2 function in vivo. In sum, the work in my thesis implies that LplA2 has a
distinct role in lipoic acid salvage compared to LplA1 and that additional, yet to be identified,
factors may be important for LplA2 function.

Figure 25. Gene arrangement of the LplA2 operon
The green arrow corresponds to the lipoic acid ligase, LplA2, which is part of the lipoic acid salvage pathway
important for scavenging lipoic acid from the environment. The black arrows correspond to the additional genes,
LLM, gcvH-L, macro, and sirTM, that are a part of the LplA2 operon.

Further analysis of the growth curves presented in this thesis showed that in the absence
of LplA2, DlipA DlplA2 and DlipA DlplA1 DlplA2 + lplA1 mutants grew when supplied with
lipoic acid, lipoamide, and digested PDH. However, surprisingly, the strains were not able to
grow when the medium was supplemented with undigested PDH, possibly indicating that S.
aureus is not able to break down the large PDH enzyme complex and import it for its own use. In
addition to supplementing with PDH, the growth medium was also supplemented with OGDH,
since both PDH and OGDH are the most abundantly found enzyme complexes in the body.
However, in the presence of digested and undigested OGDH, only the WT strain was able to
grow, indicating that LplA1 can only recognize peptide bound lipoic acid in the context of PDH
and not OGDH. Since very minimal growth of DlipA DlplA2, DlipA DlplA1 DlplA2 + lplA1,

DlipA DlplA2, and DlipA DlplA1 DlplA2 + lplA1 was observed in RPMI supplemented with
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OGDH compared to WT, I speculate that this growth may be due to some other components of
the OGDH porcine heart extract.
Since I had hypothesized that LplA1 and LplA2 can use peptide bound lipoic acid to
stimulate growth, it was surprising to see that only LplA1 was able to use peptide bound lipoic
acid specifically in the context of PDH, but not OGDH. To further explore the substrate
specificity of LplA1 for PDH and not OGDH, I analyzed the E2-PDH and E2-OGDH amino acid
sequences. I know that only the E2 subunits of OGDH and PDH contain a lipoyl moiety and
when PDH is digested with proteinase K the smallest predicted lipoyl moiety achieved is a
DKLA tripeptide (54). Analysis of both E2-PDH and E2-OGDH amino acid sequences showed
that the lipoylated lysine in PDH is flanked by an aspartate and alanine, whereas the lipoylated
lysine in OGDH is flanked by an aspartate and threonine. These tripeptides are conserved
throughout multiple species such as human, pig, rat, and mouse (Fig 13A and 13B). In addition,
the PDH enzyme complex harbors two lipoyl moieties compared to OGDH, which only has one.
To ensure that other components of the OGDH and PDH complex did not facilitate growth by a
mechanism that does not depend on lipoic acid to stimulate growth, I repeated the growth curves
with the synthetic nonlipoylated (DKA) and lipoylated tripeptide (DKLA), which has sequence
similarity with E2-PDH. Just as anticipated, DlipA DlplA2 mutant and DlipA DlplA1 DlplA2 +
lplA1 mutant grew compared to DlipA DlplA1, DlipA DlplA1 DlplA2 and DlipA DlplA1 DlplA2 +
lplA2 strain which did not grow, indicating that the growth I saw when the medium was
supplemented with digested PDH was due to the lipoyl domain and not other components of the
digested PDH enzyme complex.
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My data show that LplA1 uses peptide bound lipoic acid in the context of PDH and not
OGDH. As mentioned previously, from the genome database I know that the lipoyl lysine of
PDH and OGDH are flanked with different amino acids. Based off of this information, I
hypothesized that different amino acids may make it more difficult for the ligases to recognize
the lipoyl domain. However, contrary to my hypothesis, I observed growth for both DlipA DlplA2
and DlipA DlplA1 DlplA2 + lplA1 but not for DlipA DlplA1 and DlipA DlplA1 DlplA2 + lplA2
when the medium was supplemented with a DKLT tripeptide, which has sequence similarity with
E2-OGDH. These data indicate that it appears to be irrelevant which amino acids flank the lipoyl
lysine. Nonetheless, I speculate that the broader domain architecture of PDH may provide
specificity and allow LplA1 to use it, but not ODGH, for growth. In the future, it will be
important to repeat these growth curves with large peptide sequences of PDH and OGDH that
encompass the lipoyl domain to assess whether the lipoyl lysine in a broader domain determines
specificity.
LplA1 and LplA2 Can Directly Use Lipoic Acid and Lipoamide to Lipoylate the Apo E2
and H Subunits
Based on my findings and previous results from Zorzoli et al, 2016, I have revised our
model of S. aureus lipoic acid biosynthesis and salvage (Fig 27). My data indicate that LplA1
can directly use lipoic acid, and in some cases lipoamide, to lipoylate the H subunits (GcvH, and
GcvH-L) and one E2 protein subunit (E2-OGDH), whereas LplA2 can directly use lipoic acid to
lipoylate all S. aureus lipoyl domain-containing E2 subunits (E2-PDH, E2-OGDH, and E2BCODH) as well as the accessory H subunit (GcvH-L). LplA2 appears to lipoylate E2-OGDH at
an increased efficiency compared to LplA1, suggesting that LplA2 may be the preferred ligase
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for lipoylation of E2-OGDH. In the future, it may be interesting to explore the differences
between GcvH and GcvH-L which may provide greater insight as to why LplA1 can lipoylate
both H subunits whereas LplA2 only appears to lipoylate one H subunit. Together these data
indicate that both ligases can use different sources of lipoic acid for lipoylation, but lipoic acid
seems to be preferred.
It is a well-known fact that lipoic acid is attached to a conserved lysine via an amide
bond. For bacteria to use lipoamide or peptide bound lipoic acid, they first have to hydrolyze the
amide bond to generate free lipoic acid, which can only be achieved with an enzyme that has
lipoamidase activity. A prior review has suggested that the lipoic acid ligases may have
lipoamidase activity (39). As a result, I anticipated either LplA1, LplA2, or both ligases would
harbor lipoamidase activities, leading to similar lipoylation patterns when lipoic acid or
lipoamide are used as substrates, since lipoamidase activity results in release of free lipoic acid.
However, my data showed that all five known enzyme complexes were lipoylated using lipoic
acid, whereas only GcvH, GcvH-L, and OGDH were lipoylated using lipoamide, indicating that
lipoylation with lipoamide and lipoic acid does not result in similar patterns of lipoylation. In
addition, I detected a shift in band size on an SDS PAGE gel for reactions supplemented with
lipoic acid, whereas no shift was detected for reactions supplemented with lipoamide. Based on
these observations, I speculated that the S. aureus ligases do not have lipoamidase activity and
wondered whether the compositional differences between lipoic acid and lipoamide may explain
the different patterns of lipoylation. Composition analysis of lipoic acid and lipoamide showed
that lipoic acid consists of a dithiolane ring and a carboxyl group at its terminal end which is
important for attachment to the lysine via an amide bond. Lipoamide on the other hand, does not
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have a carboxyl group at its terminal end but instead has an amine group. These structural
differences make it impossible for lipoamide to form an amide bond with the charged lysine, as
only a carboxyl group and amine group can form an amide bond (Fig 26). As a result, I
speculated that lipoamide may form an amide bond with amino acids nearby that have a carboxyl
group. The only way an amino group can reasonably form an amide bond is with another
hydroxyl group, which can be found on amino acids such as threonine and serine. Intriguingly,
GcvH and GcvH-L both have a threonine flanking the lipoyl-lysine. Since threonine has a
carboxyl group, lipoylation of the threonine rather than the lysine may occur during the
biochemical reactions with lipoamide. It may be reasonable to suspect that both ligases, LplA1
and LplA2, have the ability to lipoylate other amino acids with carboxyl groups. Further analysis
of the E2-subunits of PDH and BKDH, which do not get lipoylated with lipoamide, showed that
neither had amino acids containing a carboxyl group flanking the lysine. However, investigation
of the E2-subunit of OGDH also did not have an amino acid with a carboxyl terminus flanking
the lysine. Nevertheless, I believe that it may be possible for lipoamide to form an amide bond
with the carboxyl group of another adjacent amino acid when used as a substrate.
In addition to having different patterns of lipoylation with lipoic acid and lipoamide, I
observed a lack of shift in band size on an SDS PAGE gel in reactions conducted with lipoamide
compared to lipoic acid. Proteins on an SDS PAGE gel are separated based on their size,
conformation, and charge. SDS is specifically important for coating the protein to provide a
uniform negative charge. However, it has been suggested that the shift seen after lipoylation with
lipoic acid is due to the increase in net negative charge after acylation of the lysine (75). If my
earlier speculations about lipoylation of threonine with lipoamide are correct, it may also explain
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why there is a lack of shift in band size in those reactions. Unlike lysine, which has a positive
charge, threonine does not have a charge. Due to a lack of charge, lipoylation of a threonine
would not alter its overall net charge, thus, these reactions might not run differently on an SDS
PAGE gel compared to the non-lipoylated control.
A.

B.

C.

Figure 26. Structural differences between lipoic acid and lipoamide
A. Lipoic acid is an organosulfur compound containing a dithiolane ring B. Lipoamide is a derivative of lipoic acid
with an amine terminal end and naturally found attached to a lysine via an amide bond. C. Lipoamide bound to a
conserved lysine via an amide bond and attached to the E2 subunit of lipoylated enzyme complexes.

Both LplA1 and LplA2 Use Octanoic Acid to Octanoylate GcvH and GcvH-L
Prior genetic evidence suggested that LplA1 in S. aureus facilitates salvage of lipoic acid
and octanoic acid to lipoylate/octanoylate apo GcvH in vitro (71). From these data, I
hypothesized that LplA2 may also facilitate such activity and octanoylate GcvH-L, since both of
them are encoded in the same operon. In order to investigate this activity and assess whether
both LplA1 and LplA2 can lipoylate GcvH and GcvH-L, I supplemented the reactions with
octanoic acid. My data indicated that both ligases use octanoic acid as a substrate to octanoylate
apo GcvH-L, however only LplA1 appeared to be able to octanoylate apo GcvH. Additional
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assessment of the ability of LplA1 and LplA2 to octanoylate E2-PDH, E2-OGDH, and E2BCODH resulted in the inability to detect a shift in band size, indicating that either the ligases
are not able to transfer octanoic acid onto E2-PDH, E2-OGDH, and E2-BCODH or that a shift in
band size is very minor and not able to be detected by resolution on an SDS-PAGE gel.
Nevertheless, it is still a possibility that the ligases octanoylate E2-PDH, E2-OGDH, and E2BCODH. One way to address this question would be to conduct octanoylation assays with
radioactive octanoic acid and detect octanoylation using autoradioagraphy. Another possible
approach would be to run the octanoylation assays on a native gel and look for a shift in band
size compared to the control indicating octanoylation.
S. aureus May Have Potential Lipoamidase Activity
Previous data indicated that LplA1 can use the lipoylated tripeptide (DKLA) to stimulate
growth in vitro. However, when I assessed the ability of LplA1 to directly use DKLA as a source
of lipoic acid in a biochemical assay, no lipoylation was detected. These data indicate that the
two ligases themselves do not have lipoamidase activity, but rather S. aureus may encode an
additional factor such as a lipoamidase in vitro that is vital for LplA1 to use peptide bound lipoic
acid. In L. monocytogenes, which also encodes two lipoic acid ligases, studies have shown that a
metal dependent lipoamidase is required for the ligases to use lipoyl tripeptides as a source of
lipoic acid (55). These data suggest that S. aureus may also encode a yet to be identified
lipoamidase that facilitates use of lipoylated tripeptides as a source of lipoic acid. In order to
determine whether or not lipoamidase activity exists in S. aureus, a possible approach would be
to conduct lipoylation assays with LplA1 and DKLA supplemented with a crude extract from a
DlipA DlipM DlipL DlplA1 DlplA2 strain to ensure that other components of lipoic acid
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biosynthesis and salvage do not interfere. If my speculations of possible lipoamidase activity are
correct, I would expect to see lipoylation of OGDH, GcvH, and GcvH-L. In addition, since a
DlipA DlplA2 strain grew in medium supplemented with DKLA, it may also be possible that other
proteins of the de novo biosynthesis pathway are important for optimal LplA1 function. To
further explore this idea, a possible approach could be to repeat the biochemical assays with
LplA1 and DKLA supplemented with LipM or LipL to assess whether they play a role in the
ability of LplA1 to use peptide bound lipoic acid. Overall, these additional experiments may help
explain the ability of LplA1 to use lipoylated tripeptides during growth in broth culture but not in
biochemical assays.

Figure 27. Lipoic acid biosynthesis and salvage pathway in S. aureus
S. aureus can acquire lipoic acid through the de novo biosynthesis pathway where octanoic acid is attached to the
acyl carrier protein and then transferred to the H subunit of GcvH with the help of the octanoyl transferase (LipM).
Next, the octanoyl moiety is converted to lipoic acid via the lipoic acid synthetase (LipA). Lastly, LipL, another
transferase, transfers the lipoyl moiety to different E2-subunits. During the lipoic acid salvage pathway, LplA1,
transfers free lipoic acid (LA), lipoamide, and octanoic acid (OA) onto GcvH and GcvH-L, and free lipoic acid (LA)
and lipoamide onto OGDH. LplA2 on the other hand, transfers free lipoic acid (LA) onto PDH, OGDH, BCODH
and free lipoic acid (LA), octanoic acid (OA) and lipoamide onto GcvH-L.
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Concluding Remarks
In this thesis, I provide direct biochemical evidence demonstrating functional lipoic acid
ligase activity for both LplA1 and LplA2 of S. aureus. Each ligase functions independently, but
has the capacity to act on both overlapping and distinct targets that comprise a range of H and E2
subunits of key metabolic enzyme complexes. Furthermore, both ligases have the potential to
universally scavenge lipoic acid and, in some cases, octanoic acid and lipoamide, thereby
expanding their functional plasticity. The ability of LplA2 to lipoylate nearly all potential targets
(all E2 proteins and GcvH-L) implies a greater metabolic reach compared to LplA1, which has a
more limited repertoire of targets (H proteins and E2-OGDH). Furthermore, the varied substrates
of these ligases (lipoic acid, lipoamide, and octanoic acid) may help explain the ease with which
S. aureus is able to infect a wide range of tissues, which harbor varied levels of free lipoic acid
or lipoyl derivatives. This is further supported by my in vitro demonstration of ligase-dependent
utilization of lipoyl peptides by S. aureus in broth culture and prior data that supports the use of
lipoyl peptides by S. aureus during infection (71). Altogether these findings highlight the
remarkable adaptability of S. aureus as it relates to nutrient acquisition and provides novel
insights into mechanisms by which the bacterium maintains metabolic homeostasis when
challenged with severe nutritional restrictions. My findings have the potential to be instrumental
in the development of novel therapeutics designed to block S. aureus acquisition of lipoic acid,
thereby perturbing bacterial replication in vivo and facilitating disease resolution.
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